var title_f4_38_4704="Gated SPECT imaging";
var content_f4_38_4704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gated SPECT imaging for false perfusion defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Stress and rest short axis images with polar maps demonstrating a fixed perfusion abnormality (present with exercise and at rest) on a Tc-99m sestamibi study in a patient with no history of a myocardial infarction. The ischemic areas appear pink. Panel B: Gated SPECT images revealing normal myocardial thickening and brightening in all regions, including the anterior wall. Thus, the perfusion abnormality noted in panel A is most likely due to a soft tissue attenuation artifact.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from DePuey, E, Rozanski, A, J Nucl Med 1995; 36:952.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4704=[""].join("\n");
var outline_f4_38_4704=null;
var title_f4_38_4705="Decapitated head IFA";
var content_f4_38_4705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Biologic control of imported fire ant by decapitating fly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows several ants whose heads have detached as a result of parasitism by lavae of decapitating flies. The introduction of decapitating flies is one potential approach to biologic control of imported fire ants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Williams DF, deShazo RD. Biological control of fire ants: an update on new techniques. Ann Allergy Asthma Immunol 2004; 93:15. Copyright &copy; 2004 American Academy of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4705=[""].join("\n");
var outline_f4_38_4705=null;
var title_f4_38_4706="SLE with end stage interstitial fibrosis chest x-ray";
var content_f4_38_4706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    End-stage interstitial fibrosis on chest radiography in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP and lateral x-rays show bibasilar interstitial fibrosis and honeycombing in a 39-year-old female patient with longstanding diagnosis of SLE.",
"    <div class=\"footnotes\">",
"     AP: anteroposterior; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4706=[""].join("\n");
var outline_f4_38_4706=null;
var title_f4_38_4707="Evaluation of the HIV-infected patient with odynophagia and dysphagia";
var content_f4_38_4707=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4707/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4707/contributors\">",
"     C Mel Wilcox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4707/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4707/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4707/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4707/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4707/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with advanced immunosuppression are at risk for esophagitis, which can be severe, and require hospitalization if the patient cannot swallow any liquids. This topic will address the evaluation of the HIV-infected patient with odynophagia and dysphagia. The treatment of esophageal candidiasis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19604928\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ESOPHAGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have not attained immune reconstitution on potent antiretroviral therapy (ART) or who are not taking ART are at risk of developing esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with a CD4 cell count &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    are at particularly high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19605015\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis may be due to Candida, herpes simplex virus (HSV), cytomegalovirus (CMV), or aphthous ulcers, although the most common cause is Candida.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of dysphagia or odynophagia should prompt concerns regarding possible esophagitis. Although oropharyngeal thrush often accompanies esophagitis with a positive predictive value of 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/2\">",
"     2",
"    </a>",
"    ], the converse is not always true. In one series, 18 percent of patients with Candida esophagitis did not have oral thrush [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two prospective studies, Candida esophagitis was detected by endoscopy in up to 64 percent of symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. If odynophagia rather than dysphagia is the most prominent symptom, candida esophagitis is less probable. The patient with severe odynophagia, without dysphagia or thrush, is more likely to have ulcerative esophagitis, such as herpes simplex virus, rather than Candida species. Rarely, esophageal lymphoma may be diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only way to establish a specific etiology for dysphagia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    odynophagia in patients with HIV is by endoscopy with biopsy (",
"    <a class=\"graphic graphic_picture graphicRef65075 \" href=\"UTD.htm?9/43/9919\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/2\">",
"     2",
"    </a>",
"    ]. As a general rule, cultures of the biopsied tissue for fungi and viruses are less specific than histology because a positive culture can be indicative only of colonization in the absence of a characteristic histology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, cultures also require several days to become positive as opposed to faster results from histologic review of tissue.",
"   </p>",
"   <p>",
"    However, most clinicians treat patients with dysphagia (especially if they also have oral thrush) with an empiric course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO after a 200 mg loading dose) prior to proceeding with endoscopy since Candida infection is so common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/7\">",
"     7",
"    </a>",
"    ]. Improvement in symptoms should be expected in five to seven days. In one series, 77 percent of patients failing empiric therapy were found to have esophageal ulcers by subsequent endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow radiography is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/9\">",
"     9",
"    </a>",
"    ]. A randomized trial comparing barium esophagography to endoscopy for symptomatic HIV-infected patients found endoscopy to be much more sensitive (98 percent versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/10\">",
"     10",
"    </a>",
"    ]. The radiographic appearance of an esophageal ulcer is not sufficiently specific to distinguish among the various etiologies. Although a multiphasic, double contrast technique may increase sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4707/abstract/9\">",
"     9",
"    </a>",
"    ], endoscopy and biopsy are still required to make a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19605023\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-infected patients with advanced immunosuppression are at risk for esophagitis, which can be severe and require hospitalization if the patient cannot swallow any liquids. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised patients who are not taking antiretroviral therapy (ART), or who have not attained immune reconstitution on HIV therapy are at risk of developing esophagitis. Patients with a CD4 cell count &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      are at particularly high risk. (See",
"      <a class=\"local\" href=\"#H19604928\">",
"       'Risk factors for esophagitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophagitis may be due to Candida, herpes simplex virus, cytomegalovirus, or aphthous ulcers, although the most common cause is Candida. (See",
"      <a class=\"local\" href=\"#H19605015\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history of dysphagia or odynophagia should prompt concerns regarding possible esophagitis. The patient with severe odynophagia, without dysphagia or thrush, is more likely to have ulcerative esophagitis, such as herpes simplex virus, rather than Candida. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only way to establish a specific etiology for dysphagia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      odynophagia in patients with HIV is by endoscopy with biopsy. As a general rule, cultures of the biopsied tissue for fungi and viruses are less specific than histology because a positive culture can be indicative only of colonization in the absence of a characteristic histology. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many clinicians treat patients with dysphagia (especially if they also have oral thrush) with an empiric course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO after a 200 mg loading dose) prior to proceeding with endoscopy since Candida infection is so common. This is especially true of patients who have readily discernable oropharyngeal thrush. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/1\">",
"      M&ouml;nkem&uuml;ller KE, Lazenby AJ, Lee DH, et al. Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy. Dig Dis Sci 2005; 50:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/2\">",
"      Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/3\">",
"      Connolly GM, Hawkins D, Harcourt-Webster JN, et al. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989; 30:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/4\">",
"      Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/5\">",
"      Chow DC, B1eikh SH, Eickhoff L, et al. Primary esophageal lymphoma in AIDS presenting as a nonhealing esophageal ulcer. Am J Gastroenterol 1996; 91:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/6\">",
"      Wilcox CM, Rodgers W, Lazenby A. Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS. Clin Gastroenterol Hepatol 2004; 2:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/7\">",
"      Wilcox CM. Short report: time course of clinical response with fluconazole for Candida oesophagitis in patients with AIDS. Aliment Pharmacol Ther 1994; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/8\">",
"      Wilcox CM, Straub RF, Alexander LN, Clark WS. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am J Med 1996; 101:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/9\">",
"      Levine MS. Radiology of esophagitis: a pattern approach. Radiology 1991; 179:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4707/abstract/10\">",
"      Connolly GM, Forbes A, Gleeson JA, Gazzard BG. Investigation of upper gastrointestinal symptoms in patients with AIDS. AIDS 1989; 3:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3726 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4707=[""].join("\n");
var outline_f4_38_4707=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19605023\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19604928\">",
"      RISK FACTORS FOR ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19605015\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19605023\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3726|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/43/9919\" title=\"picture 1\">",
"      Candida esophagitis CPC Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4708="Zinc sulfate: Patient drug information";
var content_f4_38_4708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zinc sulfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"     see \"Zinc sulfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/39/29301?source=see_link\">",
"     see \"Zinc sulfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orazinc&reg; 110 [OTC];",
"     </li>",
"     <li>",
"      Orazinc&reg; 220 [OTC];",
"     </li>",
"     <li>",
"      Zinc 15 [OTC];",
"     </li>",
"     <li>",
"      Zincate&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anuzinc;",
"     </li>",
"     <li>",
"      Rivasol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701538",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any zinc sulfate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12159 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4708=[""].join("\n");
var outline_f4_38_4708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235813\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013339\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013338\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013343\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013344\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013346\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013341\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013342\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013347\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013348\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=related_link\">",
"      Zinc sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/39/29301?source=related_link\">",
"      Zinc sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4709="Maprotiline: Patient drug information";
var content_f4_38_4709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Maprotiline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/18/16678?source=see_link\">",
"     see \"Maprotiline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Maprotiline;",
"     </li>",
"     <li>",
"      Teva-Maprotiline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to maprotiline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3450165",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Recent heart attack or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10826 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4709=[""].join("\n");
var outline_f4_38_4709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191362\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020427\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020429\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020428\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020433\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020434\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020431\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020432\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020437\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020438\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/18/16678?source=related_link\">",
"      Maprotiline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4710="Alcohol abuse and hematologic disorders";
var content_f4_38_4710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alcohol abuse and hematologic disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4710/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4710/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4710/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4710/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4710/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4710/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4710/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse is generally defined as chronic consumption of more than 80 grams of alcohol per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/1\">",
"     1",
"    </a>",
"    ]. This translates into a daily intake of one of the following: approximately 250 mL of hard liquor, more than 500 mL of fortified wine, one bottle (750 mL) of table wine, or 1.5 liters of beer (four 12 ounce cans or bottles).",
"   </p>",
"   <p>",
"    Alcohol abuse can have a variety of effects on the hematologic system, including macrocytosis with or without anemia, leukopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia. How this occurs is not completely understood. A direct toxic effect on hematopoietic cells, abnormalities in membrane phospholipids, and interference with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    utilization all may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hematologic manifestations of alcohol abuse will be discussed here. The general subject of alcohol-associated disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ALCOHOL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of alcohol on hematopoiesis may be mediated in part by metabolites of alcohol (ethanol). Ingested ethanol is metabolized in the liver in part by alcohol dehydrogenase, which oxidizes alcohol to acetaldehyde, while reducing NAD to NADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of alcoholic liver disease\", section on 'Alcohol metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that acetaldehyde accounts for some of the hematologic toxicity of alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Acetaldehyde can produce RBC protein-acetaldehyde adducts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/4\">",
"     4",
"    </a>",
"    ], which may generate immune responses against these modified proteins. Indeed, IgA and IgM anti-acetaldehyde-protein adducts have been found in alcoholics with macrocytic red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Macrocytosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANIFESTATIONS OF HEMATOLOGIC TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of alcohol-induced hematologic disorders are profoundly influenced by the patient's social and economic status, and the presence or absence of other factors, such nutritional deficiency or alcoholic cirrhosis. Most of these changes result, either directly or indirectly, in anemia. As an example, if extensive liver disease is present, the patient may develop an abnormally functioning fibrinogen or other coagulation disorders, which may initiate or exacerbate bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H21#H21\">",
"     \"Disorders of fibrinogen\", section on 'Liver disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858365#H5858365\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Hypocoagulability in cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse, coupled with the patient&rsquo;s social and economic status, can lead to anemia via the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient also has a chronic infection (eg, tuberculosis), the anemia of chronic disease may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      .) Treatment of the underlying infection(s) will reverse this component of the patient's anemia.",
"     </li>",
"     <li>",
"      The presence of cirrhosis can lead to bleeding from esophageal and gastric varices; bleeding can also occur from alcoholic gastritis. Continued bleeding may eventually lead to iron deficiency anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of portal hypertension may lead to congestive splenomegaly (hypersplenism), with splenic trapping of red cells, white cells,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelets and resulting cytopenia(s). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol abuse is probably the most common cause of nutritional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency in the United States, leading to a megaloblastic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alcohol directly interferes with erythropoiesis and blocks the response to folate in subjects who are folate deficient. Both macrocytosis (see below) and stomatocytosis are regular features on the peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link&amp;anchor=H14#H14\">",
"     \"Stomatocytosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Macrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even before anemia appears, approximately 90 percent of alcoholics have a macrocytosis (mean corpuscular volume [MCV] between 100 to 110 femtoliters [fL]) which is easily detected by automated counters [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. Alcohol-induced macrocytosis occurs even though patients are folate and cobalamin replete and do not have liver disease. The mechanism is unknown, but it takes two to four months for the macrocytosis to disappear after the patient becomes abstinent.",
"   </p>",
"   <p>",
"    Attribution of macrocytosis to alcohol abuse requires the exclusion of other causes of this abnormality. The most common are megaloblastic anemia (eg, B12 or folate deficiency), liver disease, hypothyroidism, use of antimetabolite drugs, and myelodysplastic syndromes (",
"    <a class=\"graphic graphic_table graphicRef66772 \" href=\"UTD.htm?9/47/9980\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H4#H4\">",
"     \"Macrocytosis\", section on 'Alcoholism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in a study of 300 patients in a New York City hospital who had a MCV &gt;100 fL, the most common causes were drugs (frequently for treatment of HIV) and alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/9\">",
"     9",
"    </a>",
"    ]. Less common causes were liver disease and elevated reticulocytes. Megaloblastic anemia accounted for less than 10 percent of cases.",
"   </p>",
"   <p>",
"    Alcoholism can sometimes be difficult to distinguish from megaloblastic anemia due to folate or cobalamin deficiency. The latter diagnoses are suggested by the findings of an MCV above 110 fL, macroovalocytosis of the circulating red cells, teardrop-shaped red cells, and hypersegmented neutrophils on the blood smear (ie, more than 5 percent of neutrophils having five lobes) (",
"    <a class=\"graphic graphic_picture graphicRef74901 graphicRef58820 \" href=\"UTD.htm?6/38/6762\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Measurement of the serum cobalamin level and red blood cell folate levels will usually establish the appropriate diagnosis. Measurement of serum folate is not used in this setting, since alcohol lowers the folate level even in patients who are not truly deficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of alcohol-induced macrocytosis, with or without anemia, is abstinence. Return of the MCV to normal also confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decreased red cell production",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, anemia in alcoholic patients is often multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to the direct toxic effect of alcohol, iron deficiency due to gastrointestinal bleeding, nutritional folate deficiency from the effects of a poor diet, and the anemia of chronic disease may be present. Each of these disorders impairs RBC production, which should be associated with a low or low normal reticulocyte count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=see_link\">",
"     \"Anemias due to decreased red cell production\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although decreased red cell production is generally responsible for the anemia, there may also be a hemolytic component in some alcoholic patients. Two factors may contribute to this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic sequestration due to an enlarged spleen (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spur cell hemolysis in severe alcoholic cirrhosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"      </a>",
"      ). In an interesting case report, orthotopic liver transplant cured the spur cell anemia, which recurred when the patient resumed alcohol abuse and the liver graft failed, implicating both liver failure and alcohol abuse as causes of spur cell anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bone marrow aspiration and biopsy are usually unnecessary in the anemia associated with alcohol abuse. If obtained, approximately one-fourth of patients will show the presence of ringed sideroblasts in erythroid precursors (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/1\">",
"     1",
"    </a>",
"    ]. Very heavy alcohol consumption may also be associated with the appearance of vacuoles in proerythroblasts and granulocytic precursors, the cause of which is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, in a series of 144 patients from Finland, 24 percent of severe alcohol abusers had vacuolated proerythroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The marrow may also become distinctly hypoplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/10\">",
"     10",
"    </a>",
"    ] and even aplastic with pancytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/11\">",
"     11",
"    </a>",
"    ]. Abstinence results in reversal of the hypoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LEUKOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholics appear to be immunocompromised and are susceptible to recurrent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]. Leukopenia, due to a fall in the neutrophil count, occurs in approximately 8 percent of hospitalized alcoholics, and there may also be a hard-to-characterize defect in neutrophil function. The presence of alcoholic cirrhosis, portal hypertension, and splenomegaly can further lower the white blood cell count (ie, hypersplenism).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some series, as many as 80 percent of hospitalized alcoholics have mild thrombocytopenia, defined as a platelet count below",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]. An enlarged spleen in the patient with alcoholic cirrhosis is thought to play an important role, but alcohol also has a direct toxic effect on megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]. The platelet count rarely falls below",
"    <span class=\"nowrap\">",
"     10,000/microL;",
"    </span>",
"    as a result, splenectomy to control thrombocytopenic bleeding is almost never necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ]. In some patients, platelet function may also be abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H21#H21\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Liver disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858437#H5858437\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Platelet level and function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rebound thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of alcohol abstinence and ingestion of a reasonable diet (typically occurring after hospitalization) often results in a platelet \"rebound\" at one to two weeks, with the platelet count often reaching 600,000 to",
"    <span class=\"nowrap\">",
"     900,000/microL.",
"    </span>",
"    This is a normal and transient response to the prior episode of thrombocytopenia, and does not require hematologic consultation or treatment. The platelet count returns to normal levels within another 7 to 10 days without further therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=see_link\">",
"       \"Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284394\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284402\">",
"    <span class=\"h2\">",
"     Definition of alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse has been defined as chronic consumption of more than 80 grams of ethanol per day, or a daily intake of approximately 250 mL of hard liquor, 500 mL of fortified wine, 750 mL of table wine, or 1.5 liters of beer (four 12 ounce cans or bottles).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284438\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematologic consequences of alcohol abuse include any or all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia, often macrocytic, with components due to decreased red cell production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased red cell destruction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukopenia, most often due to trapping of leukocytes in an enlarged spleen (ie, hypersplenism). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Leukopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombocytopenia, often due to hypersplenism, although platelet dysfunction may be present in some individuals. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased bleeding due to an acquired coagulopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858365#H5858365\">",
"       \"Coagulation abnormalities in patients with liver disease\", section on 'Hypocoagulability in cirrhosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284547\">",
"    <span class=\"h2\">",
"     Complicating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional factors which may affect the degree of hematologic derangement in the subject with alcohol abuse include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor diet, with resulting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency",
"     </li>",
"     <li>",
"      Coexisting infection",
"     </li>",
"     <li>",
"      Advanced liver disease, with bleeding varices, hypersplenism, acquired coagulopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284555\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in a patient with varying degrees of macrocytic anemia and cytopenias includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deficiencies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cobalamin",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome",
"     </li>",
"     <li>",
"      Drug toxicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284563\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no effective treatment for the hematologic consequences of alcohol abuse other than cessation of alcohol intake along with resumption of an adequate diet.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrocytic anemia may take many months to disappear after cessation of alcohol intake.",
"     </li>",
"     <li>",
"      The hematologic manifestations secondary to portal hypertension and hypersplenism (eg, bleeding varices, cytopenias) may remain unchanged.",
"     </li>",
"     <li>",
"      Alcohol abstinence and ingestion of a reasonable diet may result in a temporary period of rebound thrombocytosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rebound thrombocytosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/1\">",
"      Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/2\">",
"      Girard DE, Kumar KL, McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am 1987; 1:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/3\">",
"      Lieber CS. Metabolism and metabolic effects of alcohol. Semin Hematol 1980; 17:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/4\">",
"      Niemel&auml; O, Parkkila S. Alcoholic macrocytosis--is there a role for acetaldehyde and adducts? Addict Biol 2004; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/5\">",
"      Koivisto H, Hietala J, Anttila P, et al. Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications. J Lab Clin Med 2006; 147:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/6\">",
"      Malik P, Bogetti D, Sileri P, et al. Spur cell anemia in alcoholic cirrhosis: cure by orthotopic liver transplantation and recurrence after liver graft failure. Int Surg 2002; 87:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/7\">",
"      Latvala J, Parkkila S, Niemel&auml; O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004; 28:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/8\">",
"      Sepp&auml; K, Sillanaukee P, Saarni M. Blood count and hematologic morphology in nonanemic macrocytosis: differences between alcohol abuse and pernicious anemia. Alcohol 1993; 10:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/9\">",
"      Savage DG, Ogundipe A, Allen RH, et al. Etiology and diagnostic evaluation of macrocytosis. Am J Med Sci 2000; 319:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/10\">",
"      Conrad ME, Barton JC. Anemia and iron kinetics in alcoholism. Semin Hematol 1980; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4710/abstract/11\">",
"      Nakao S, Harada M, Kondo K, et al. Reversible bone marrow hypoplasia induced by alcohol. Am J Hematol 1991; 37:120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7151 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4710=[""].join("\n");
var outline_f4_38_4710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5284394\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ALCOHOL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANIFESTATIONS OF HEMATOLOGIC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decreased red cell production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LEUKOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rebound thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5284394\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284402\">",
"      Definition of alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284438\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284547\">",
"      Complicating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284555\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284563\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7151|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9942\" title=\"picture 1A\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/47/4854\" title=\"picture 1B\">",
"      Megaloblastic smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 2\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/47/9980\" title=\"table 1\">",
"      Causes of macrocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=related_link\">",
"      Anemias due to decreased red cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4711="Nocturnal leg cramps";
var content_f4_38_4711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nocturnal leg cramps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4711/contributors\">",
"     John W Winkelman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4711/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal leg cramps, a common lower extremity condition that produces pain and can disrupt sleep, are reviewed here. Other nighttime disorders of leg movement, including restless legs syndrome and periodic limb movements of sleep, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"     \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOCTURNAL LEG CRAMPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal leg cramps are common and frequently unreported to clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They are present in nearly 50 percent of those over the age of 50, have an increased prevalence with age, and show no gender preference. Roughly 40 percent of those with nocturnal leg cramps report having such symptoms at least three times per week, and 5 to 10 percent report nightly cramping.",
"   </p>",
"   <p>",
"    Leg cramps are characterized by sudden muscle tightness, most commonly in the foot, thigh, or calf, last from seconds to many minutes, and are relieved by forceful stretching of the affected muscles. The vast majority of individuals have such cramps only at night. Their primary morbidity is pain and sleep disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leg cramps can be idiopathic (the most common), associated with structural disorders or leg positioning, or related to extracellular fluid volume depletion and electrolyte disturbances.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structural disorders such as flat feet, genu recurvatum, and the hypermobility syndrome may predispose to leg cramps. A family history is common in these circumstances.",
"     </li>",
"     <li>",
"      Prolonged sitting, inappropriate leg position during sedentary activity, or living or working on concrete flooring may be correlated with an increased occurrence of leg cramps.",
"     </li>",
"     <li>",
"      Leg cramps may result from extracellular volume depletion (eg, due to diuretics, excessive sweating without sufficient salt replacement, or fluid removal during hemodialysis) and the dialysis disequilibrium syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"       \"Dialysis disequilibrium syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy-related leg cramps may be due, in part, to low serum magnesium, which may respond to magnesium supplementation, although results of trials using such therapy are mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic disorders including Parkinson disease, myopathies, neuropathies, radiculopathies, and motor neuron diseases are often accompanied by leg cramps [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metabolic diseases associated with leg cramps include diabetes, hypoglycemia, alcoholism, hypothyroidism, and metabolic myopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise-associated muscle cramping (EAMC) is defined as an involuntary, painful contraction of skeletal muscle during or after exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other causes of leg cramps include various medications and other medical conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/7,9-17\">",
"       7,9-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medications for which the evidence of an association with leg cramps is the strongest, although still unproven, include inhaled long-acting beta agonists (LABA), potassium-sparing diuretics, and thiazide-like diuretics. Analysis of a population-derived pharmacy database involving 24,417 individuals found that patients were more likely to receive a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      prescription for nocturnal leg cramps during the year after starting a drug from one of these classes, compared with the preceding year (sequence ratios for LABA, potassium-sparing and thiazide diuretics of 2.42 [95% CI 2.02-2.89], 2.12 [95% CI 1.61-2.78], and 1.48 [95% CI 1.29-1.68], respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/17\">",
"       17",
"      </a>",
"      ]. Only small increased risks were seen for loop diuretics and statins.",
"      <br/>",
"      <br/>",
"      Other medications that may cause cramps include other beta agonists, beta blockers with intrinsic sympathomimetic activity, angiotensin II receptor antagonists, benzodiazepines, paratide, teriparatide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"       tolcapone",
"      </a>",
"      , clofibrate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and oral contraceptives.",
"     </li>",
"     <li>",
"      Other unusual causes include anemia, Raynaud syndrome, opioid withdrawal, nonalcoholic cirrhosis, and bariatric surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with the most common form of leg cramps have no fluid or electrolyte imbalance. Observed pathophysiologic changes include an increased frequency of muscle action potentials due to motor neuron hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/10\">",
"     10",
"    </a>",
"    ]. This results in depletion of muscle adenosine triphosphate; cytosolic accumulation of calcium then prevents muscle relaxation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may describe numerous types of leg pain as cramps. The physical examination may be helpful only in that it is usually normal with idiopathic leg cramps. A careful history and physical examination can exclude the majority of disorders in the differential diagnosis, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contractures (which occur in metabolic myopathies and thyroid disease)",
"     </li>",
"     <li>",
"      Tetany (due to hypocalcemia, hypomagnesemia, and metabolic alkalosis)",
"     </li>",
"     <li>",
"      Dystonias (occupational cramps and those related to dopamine antagonists [eg, antipsychotic medications or antiemetics] or Parkinson&rsquo;s disease)",
"     </li>",
"     <li>",
"      Myalgias (due to some drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Restless legs syndrome (which also occurs at rest, predominantly in the evening, and is characterized by a need to move the affected limb and at times, by involuntary brief movements, but does not involve sustained contraction of muscles) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intermittent claudication (which occurs during limb use and is relieved by rest)",
"     </li>",
"     <li>",
"      Compartment syndromes (occurring after excessive running)",
"     </li>",
"     <li>",
"      Peripheral neuropathy (characterized by dysesthesias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      muscle weakness but not sustained muscle contractions)",
"     </li>",
"     <li>",
"      Peripheral vascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse, recurrent, or severe muscle cramping should prompt an evaluation for hypocalcemia, although the plasma calcium concentration is normal in patients with idiopathic cramps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevention and treatment of benign nocturnal leg cramps begins with nonpharmacologic therapy. Cramps often resolve on their own or with nonpharmacologic interventions alone. The best data for pharmacologic therapy is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , but this drug is no longer routinely recommended for nocturnal leg cramps. Weaker evidence exists for the efficacy of vitamin B complex, naftidrofuryl (though not available in the United States), and calcium channel blockers, and these medications should be tried before considering quinine or other less well-studied medications. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Nonpharmacologic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Pharmacotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies are used for both the prevention and treatment of nocturnal leg cramps, but the evidence supporting the efficacy of any of these approaches is very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following preventive measures may be beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In generally sedentary patients, riding a stationary bicycle for a few minutes before retiring",
"     </li>",
"     <li>",
"      Stretching exercises. These exercises can be performed in the weight-bearing position. They are held for 10 to 20 seconds and are repeated three to five times in succession, four times daily for one week, then twice daily in the evening, and again before retiring thereafter (",
"      <a class=\"graphic graphic_picture graphicRef70744 \" href=\"UTD.htm?33/20/34126\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/19\">",
"       19",
"      </a>",
"      ]. One clinical trial, however, failed to confirm the benefit of this approach, although all of the trial patients were on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      at baseline, and many continued the drug during the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Further support for the efficacy of stretching was provided by another randomized trial, which was not included in the 2012 systematic review [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/21\">",
"       21",
"      </a>",
"      ]. In this trial, involving 80 patients over 55 years of age with a mean of 3.2 to 3.4 cramps nightly, a six-week program of calf and hamstring muscle stretching before sleep significantly decreased the frequency of nocturnal leg cramps compared with not stretching (mean difference of -1.2 cramps nightly, 95% CI -0.6 to -1.8). Additionally, cramp severity was decreased in the treatment group but not in the controls.",
"     </li>",
"     <li>",
"      Using long-countered shoes and other proper foot gear (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=see_link\">",
"       \"Joint protection program for the lower limb\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Keeping the bed covers at the foot of the bed loose and not tucked in",
"     </li>",
"     <li>",
"      Maintaining adequate hydration, particularly in older adults and patients on diuretics. Avoidance of alcohol and caffeine may also be helpful. Exercising in extreme heat should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a cramp occurs, nonpharmacologic interventions that may be beneficial include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Walking or leg jiggling followed by leg elevation",
"     </li>",
"     <li>",
"      A hot shower with the stream directed at the cramp area of the body, usually for five minutes, or a warm tub bath",
"     </li>",
"     <li>",
"      Ice massage",
"     </li>",
"     <li>",
"      Correction of fluid and electrolyte abnormalities, if present (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    has been the best-studied drug for nocturnal leg cramps and has been found effective in some well-designed randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/22\">",
"     22",
"    </a>",
"    ]. However, quinine is no longer routinely recommended for the treatment of nocturnal leg cramps due to the potential for serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening side effects (eg, cardiac arrhythmias, thrombocytopenia, HUS-TTP, and severe hypersensitivity reactions) that occur in 2 to 4 percent of patients, important drug interactions, and evidence for only modest benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/23\">",
"     23",
"    </a>",
"    ]. An FDA warning issued in December 2006 and reaffirmed in 2010 stated that, due to these potential serious events, the risks associated with quinine use do not justify its use in the",
"    <span class=\"nowrap\">",
"     unapproved/unlabeled",
"    </span>",
"    prevention and treatment of leg cramps [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Quinine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medications have been less well-studied. A 2010 systematic review of prospective trials identified limited data to support the use of several agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/23\">",
"     23",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vitamin B complex, including vitamin B6, 30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Naftidrofuryl, which is unavailable in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Calcium channel blockers, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (120 to 180 mg at bedtime) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following medications have also been used for nocturnal leg cramps with variable success [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/19,29-35\">",
"     19,29-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      (Benadryl) 12.5 to 50 mg nightly",
"     </li>",
"     <li>",
"      Vitamin E [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/30\">",
"       30",
"      </a>",
"      ], although the efficacy of this agent has not been confirmed in randomized studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Muscle relaxants, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32693?source=see_link\">",
"       carisoprodol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/11/36021?source=see_link\">",
"       orphenadrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       Chloroquine",
"      </a>",
"      phosphate (250 mg daily for two to three weeks, followed by 250 to 500 mg once per week) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/33\">",
"       33",
"      </a>",
"      ]. We have also used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      sulfate (200 mg daily for two weeks, then once per week) with good results.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      (600 mg daily with increased doses as necessary) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Shakuyaku-kanzo-to granule, used in hemodialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of randomized trials comparing magnesium supplementation with placebo identified four trials involving 322 patients with idiopathic (primarily nocturnal) leg cramps; meta-analysis of the trials found no evidence of significant benefit in the frequency or severity of cramping with magnesium therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/37\">",
"     37",
"    </a>",
"    ]. Three trials involving a total of 202 women with pregnancy-associated leg cramps were identified in the systematic review; only one found benefit.",
"   </p>",
"   <p>",
"    We generally use pharmacotherapy only in patients who fail nonpharmacologic measures, given the risk of serious adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    and the relatively weak data for benefit of other agents. In these patients, we typically do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We use mineral and vitamin supplementation before using prescription medications, including assuring adequate supplementation with calcium; magnesium, the use of which is limited to patients with pregnancy-related cramps; iron, in patients who have iron-deficient anemia; and vitamins E and B6.",
"     </li>",
"     <li>",
"      We advise avoidance of drugs known to cause cramping. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the measures above are ineffective, we first try",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (25 mg) at bedtime, and, if it is ineffective, we prescribe a calcium channel blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      (30 mg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (120 to 180 mg) each evening.",
"     </li>",
"     <li>",
"      In patients with muscle cramping that is persistent or severe or occurs in unusual locations, such as upper back or abdominals, the author has given a two-week trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      If cramps have resolved with this treatment, it is then withheld until symptoms return, but the cramping may remit for extended periods of time in the author's experience.",
"     </li>",
"     <li>",
"      We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      after the above measures have failed, with particular care in older patients because of the increased risk of side effects in such patients in the author's experience.",
"     </li>",
"     <li>",
"      If the measures above fail,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      can be considered as long as the patient is informed of the potential adverse events and understands the level of risk relative to the benign (although painful) nature of leg cramps. The FDA specifically recommends that healthcare professionals should discuss with patients the warning signs of thrombocytopenia and that patients should be encouraged to read the Medication Guide given to them at the pharmacy before starting quinine sulfate and each time they get a refill [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/25\">",
"       25",
"      </a>",
"      ]. However, the author advises the use of 6 ounces (180 mL) of tonic water, rather than prescription quinine, and only if cramps have persisted or are severe and disabling. We use such treatment rarely and do not use it on a daily basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2305150\">",
"    <span class=\"h2\">",
"     Nocturnal leg cramps in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal leg cramps have been reported in 7.3 percent of children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/38\">",
"     38",
"    </a>",
"    ]. Peak occurrence is 16 to 18 years of age, with no cases reported less than eight years of age. Pediatric nocturnal leg cramps are typically benign, self-limited, and infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87361887\">",
"    <span class=\"h1\">",
"     OTHER NOCTURNAL LEG MOVEMENT CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sleep starts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnic jerks, also termed benign hypnic myoclonus, are common sudden jerking contractures of the limbs that occur during the transition to, or very shortly after, falling asleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4711/abstract/40\">",
"     40",
"    </a>",
"    ]. These sleep starts may awaken the patient, and the severity of the movement can occasionally be frightening. They seldom recur after falling back to sleep. No definite cause is known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Sleep starts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The condition is self-limited; treatment includes reassurance of the benign nature of the disturbance. Use of caffeinated beverages should be avoided. Occasionally, sleep starts and restless legs syndrome coexist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nocturnal myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varieties of sudden movement that occur during sleep or sleep transitions are partial myoclonic jerks, massive myoclonic jerks (hypnic jerks), and periodic movements of sleep. These conditions are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and evaluation of myoclonus\", section on 'Jerks associated with sleep'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"     \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodic movements of sleep (nocturnal myoclonus) consist of stereotyped dorsiflexion of the toes and feet, sometimes with flexion of the knees and hips occurring roughly every 10 to 30 seconds. These movements occur in relaxed wakefulness or during sleep, are common in restless legs syndrome (but can occur in those without this disorder), and can disrupt sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"     \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturnal leg cramps are common, are frequently unreported to clinicians, and occur in all decades of life. The most important morbidity of benign nocturnal leg and foot cramps is that they produce pain and often disturb sleep. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nocturnal leg cramps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leg cramps are most commonly idiopathic but may also be associated with structural disorders or leg positioning or related to extracellular fluid volume depletion and electrolyte disturbances. Other causes include neurologic and metabolic disorders and pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may describe numerous types of leg pain as cramps. The physical examination may be helpful only in that it is usually normal with idiopathic leg cramps. A careful history and physical examination can exclude the majority of disorders in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diffuse, recurrent, or severe muscle cramping should prompt an evaluation for hypocalcemia, although the plasma calcium concentration is normal in patients with idiopathic cramps. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention and treatment of benign nocturnal leg cramps begins with nonpharmacologic therapy. The best data for pharmacologic therapy are with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      , but this drug is no longer routinely recommended for nocturnal leg cramps because of risks of serious adverse effects. Weaker evidence exists for the efficacy of vitamin B complex, naftidrofuryl (though not available in the United States), and calcium channel blockers, and these medications should be tried before considering quinine or other less well-studied medications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep starts are a commonly occurring, sudden, jerking contraction of the limbs that occurs shortly after falling asleep and that may awaken the patient. They seldom recur after falling back to sleep. No definite cause is known. Treatment includes reassurance of the benign nature of the disturbance. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sleep starts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic limb movements of sleep (nocturnal myoclonus) consist of stereotyped dorsiflexion of the toes and feet, sometimes with flexion of the knees and hips roughly every 10 to 30 seconds. These movements are common in the restless legs syndrome and can disrupt sleep. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nocturnal myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818506\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd Edition, Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/2\">",
"      Naylor JR, Young JB. A general population survey of rest cramps. Age Ageing 1994; 23:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/3\">",
"      Dahle LO, Berg G, Hammar M, et al. The effect of oral magnesium substitution on pregnancy-induced leg cramps. Am J Obstet Gynecol 1995; 173:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/4\">",
"      Nygaard IH, Valb&oslash; A, Pethick SV, B&oslash;hmer T. Does oral magnesium substitution relieve pregnancy-induced leg cramps? Eur J Obstet Gynecol Reprod Biol 2008; 141:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/5\">",
"      Sohrabvand F, Shariat M, Haghollahi F. Vitamin B supplementation for leg cramps during pregnancy. Int J Gynaecol Obstet 2006; 95:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/6\">",
"      Parisi L, Pierelli F, Amabile G, et al. Muscular cramps: proposals for a new classification. Acta Neurol Scand 2003; 107:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/7\">",
"      Maquirriain J, Merello M. The athlete with muscular cramps: clinical approach. J Am Acad Orthop Surg 2007; 15:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/8\">",
"      Schwellnus MP. Muscle cramping in the marathon : aetiology and risk factors. Sports Med 2007; 37:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/9\">",
"      Whiteley AM. Cramps, stiffness and restless legs. Practitioner 1982; 226:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/10\">",
"      McGee SR. Muscle cramps. Arch Intern Med 1990; 150:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/11\">",
"      Zimlichman R, Krauss S, Paran E. Muscle cramps induced by beta-blockers with intrinsic sympathomimetic activity properties: a hint of a possible mechanism. Arch Intern Med 1991; 151:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/12\">",
"      Atreja A, Abacan C, Licata A. A 51-year-old woman with debilitating cramps 12 years after bariatric surgery. Cleve Clin J Med 2003; 70:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/13\">",
"      Morii H. [Safety profile of raloxifene]. Clin Calcium 2004; 14:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/14\">",
"      Baskol M, Ozbakir O, Cokun R, et al. The role of serum zinc and other factors on the prevalence of muscle cramps in non-alcoholic cirrhotic patients. J Clin Gastroenterol 2004; 38:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/15\">",
"      Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008; 65:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/16\">",
"      Gupta S, Gupta V, Kapoor B, Kapoor V. Pyrazinamide induced hyperuricaemia presenting as severe bilateral leg cramps. J Indian Med Assoc 2007; 105:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/17\">",
"      Garrison SR, Dormuth CR, Morrow RL, et al. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med 2012; 172:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/18\">",
"      Blyton F, Chuter V, Walter KE, Burns J. Non-drug therapies for lower limb muscle cramps. Cochrane Database Syst Rev 2012; 1:CD008496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/19\">",
"      Daniell HW. Simple cure for nocturnal leg cramps. N Engl J Med 1979; 301:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/20\">",
"      Coppin RJ, Wicke DM, Little PS. Managing nocturnal leg cramps--calf-stretching exercises and cessation of quinine treatment: a factorial randomised controlled trial. Br J Gen Pract 2005; 55:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/21\">",
"      Hallegraeff JM, van der Schans CP, de Ruiter R, de Greef MH. Stretching before sleep reduces the frequency and severity of nocturnal leg cramps in older adults: a randomised trial. J Physiother 2012; 58:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/22\">",
"      El-Tawil S, Al Musa T, Valli H, et al. Quinine for muscle cramps. Cochrane Database Syst Rev 2010; :CD005044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/23\">",
"      Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2010; 74:691.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration Medwatch: Quinine products. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     Qualaquin (quinine sulfate): New Risk Evaluation and Mitigation Strategy - Risk of serious hematological reactions. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm218424.htm (Accessed on July 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/26\">",
"      Chan P, Huang TY, Chen YJ, et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol 1998; 38:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/27\">",
"      Young JB, Connolly MJ. Naftidrofuryl treatment for rest cramp. Postgrad Med J 1993; 69:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/28\">",
"      Voon WC, Sheu SH. Diltiazem for nocturnal leg cramps. Age Ageing 2001; 30:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/29\">",
"      Baltodano N, Gallo BV, Weidler DJ. Verapamil vs quinine in recumbent nocturnal leg cramps in the elderly. Arch Intern Med 1988; 148:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/30\">",
"      Ayres S Jr, Mihan R. Nocturnal leg cramps (systremma): a progress report on response to vitamin E. South Med J 1974; 67:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/31\">",
"      Brunetti LL, Lauzardo MG, Baucom MP, et al. Treatment of nocturnal leg cramps. Arch Intern Med 1994; 154:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/32\">",
"      Lee HB. Cramp in the elderly. Br Med J 1976; 2:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/33\">",
"      More on muscle cramps. Drug Ther Bull 1983; 21:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/34\">",
"      Guay DR. Are there alternatives to the use of quinine to treat nocturnal leg cramps? Consult Pharm 2008; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/35\">",
"      Hyodo T, Taira T, Takemura T, et al. Immediate effect of Shakuyaku-kanzo-to on muscle cramp in hemodialysis patients. Nephron Clin Pract 2006; 104:c28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/36\">",
"      Serrao M, Rossi P, Cardinali P, et al. Gabapentin treatment for muscle cramps: an open-label trial. Clin Neuropharmacol 2000; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/37\">",
"      Garrison SR, Allan GM, Sekhon RK, et al. Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev 2012; 9:CD009402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/38\">",
"      Leung AK, Wong BE, Chan PY, Cho HY. Nocturnal leg cramps in children: incidence and clinical characteristics. J Natl Med Assoc 1999; 91:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/39\">",
"      Leung AK, Wong BE, Cho HY, Chan PY. Leg cramps in children. Clin Pediatr (Phila) 1997; 36:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4711/abstract/40\">",
"      Walters AS. Clinical identification of the simple sleep-related movement disorders. Chest 2007; 131:1260.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5177 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4711=[""].join("\n");
var outline_f4_38_4711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOCTURNAL LEG CRAMPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2305150\">",
"      Nocturnal leg cramps in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87361887\">",
"      OTHER NOCTURNAL LEG MOVEMENT CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sleep starts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nocturnal myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20818506\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5177|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/20/34126\" title=\"picture 1\">",
"      Posterior leg stretch wall",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=related_link\">",
"      Joint protection program for the lower limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4712="Adjuvant radiation therapy for malignant gliomas";
var content_f4_38_4712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant radiation therapy for malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4712/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and glioblastoma (GBM) based upon their histopathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant gliomas are best managed with a combined modality approach, incorporating adjuvant postoperative radiation therapy (RT) and adjuvant chemotherapy following initial surgery. Postoperative RT is discussed in this topic.",
"   </p>",
"   <p>",
"    Other patient management topics that are covered separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with suspected brain tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initial surgical management of malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy following surgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrent malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link\">",
"       \"Management of recurrent malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anaplastic oligodendroglial tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=see_link\">",
"       \"Treatment of oligodendroglial tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elderly patients (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=see_link\">",
"       \"Management of malignant gliomas in elderly patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Experimental approaches in malignant glioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"       \"Experimental treatment approaches for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A histologic diagnosis is required for optimal treatment of patients with brain tumors. This can be accomplished either at the time of surgical resection or with a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a newly diagnosed malignant glioma, maximal surgical resection consistent with preservation of neurologic function is preferred. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even patients who undergo a gross total resection of their malignant glioma have a high recurrence rate. Gross total resection refers to the removal of the visibly abnormal tissue seen intraoperatively or as enhancing on post-gadolinium T1-weighted MRI. Most gliomas are infiltrative tumors with microscopic disease extending into the adjacent brain parenchyma to the gross tumor. Adjuvant RT directed to residual microscopic and gross disease improves local control and survival after resection.",
"   </p>",
"   <p>",
"    The effect of RT on survival was initially demonstrated in patients treated with whole brain RT (WBRT). Subsequent advances in RT technique have utilized improved imaging of the tumor and focused on RT techniques that maximize treatment to the tumor while minimizing radiation to normal brain tissue. Focal external beam RT, termed involved field RT (IFRT), has replaced WBRT as the standard approach. Some types of involved field RT include 3D-conformal RT and intensity modulated RT.",
"   </p>",
"   <p>",
"    There are no data comparing optimal dose and schedule in grade III gliomas versus glioblastoma. However, many radiation oncologists use a dose of 59.4 Gy in 1.8 Gy fractions for grade III tumors versus 60 Gy in 2 Gy fractions for grade IV tumors with the expectation that the 10 percent dose reduction per fraction may lead to reduced late normal tissue effects for patients with projected longer term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Survival benefit from RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of adjuvant WBRT was shown in at least three randomized trials conducted in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a representative trial from the Brain Tumor Study Group (BTSG), the addition of adjuvant WBRT to surgical resection increased median survival from 14 to 36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/3\">",
"     3",
"    </a>",
"    ]. Other data from the BTSG demonstrated the superiority of adjuvant RT compared to adjuvant chemotherapy alone as a postoperative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate doses of RT are required to maximize the survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. This was illustrated by a retrospective review of 91 patients with malignant glioma who had a stereotactic biopsy followed by RT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/4\">",
"     4",
"    </a>",
"    ]. Regardless of extent of resection, patients who had RT doses of 50 to 60 Gy had a longer median survival than those who received lower postoperative RT doses (19 versus 11 weeks for patients with GBM and 27 versus 11 weeks for AA).",
"   </p>",
"   <p>",
"    Dose escalation above 60 Gy with WBRT has not been shown to provide further benefit. In two randomized trials, there were no significant differences in tumor control or survival in patients treated with 60 Gy of WBRT or 60 Gy followed by a 10 Gy tumor boost [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major complications following WBRT included progressive and irreversible radiation necrosis, with accompanying small blood vessel injury, vascular occlusion, and demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/8\">",
"     8",
"    </a>",
"    ]. Other late sequelae include asymptomatic narrowing of large vessels, delayed RT-induced leukoencephalopathy, and secondary neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These serious complications of WBRT led to the adoption of IFRT as a way to minimize toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H16#H16\">",
"     \"Complications of cranial irradiation\", section on 'Radiation necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Involved field radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved field RT has become the standard approach for adjuvant RT. The rationale for limiting the RT field is based upon the observation that recurrent malignant glioma following WBRT develops within 2 cm of the original tumor site in 80 to 90 percent of cases, while fewer than 10 percent are multifocal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To encompass infiltrating tumor cells, the RT dose (typically 60 Gy) is usually delivered to the tumor plus a margin of radiographically apparently normal tissue. If the tumor is defined based upon contrast enhancement, a margin of 2.0 to 3.0 cm is often used, while if the RT field is defined by T2-weighted MRI abnormality, a 1.0 to 2.0 cm margin is used.",
"   </p>",
"   <p>",
"    The shift from WBRT to IFRT has not changed the pattern of treatment failure or altered the percentage of patients with multifocal failures. As an example, in a series of 42 patients with recurrent grade III glioma or glioblastoma following IFRT, all recurrences were within 2 cm of the original tumor site, while two patients had a second lesion both inside and outside the 2 cm margin and two patients had a distant second lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     3D conformal RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of three-dimensional (3D) treatment planning has decreased the amount of normal brain irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current 3D conformal RT (3D-CRT) utilizes CT-based treatment planning with dosimetric software to create composite treatment plans. Fusion of planning CT with MRI is extremely helpful in assisting with target definition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The incorporation of PET or MR spectroscopy data is still largely investigational and most commonly used to define boost volumes rather than primary target volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Photons of 6 to 8 megavolts (MV) are most commonly used with three to four angled radiation fields.",
"   </p>",
"   <p>",
"    Radiation oncologists work with medical physicists and dosimetrists to design optimal treatment plans. Considerations in treatment planning include beam energy, field size and shape, beam modifiers, irradiated tissue density and heterogeneity, and radiation tolerance of surrounding normal tissues.",
"   </p>",
"   <p>",
"    No benefit in progression-free or overall survival has been demonstrated although these techniques help avoid excess RT to normal brain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intensity-modulated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity-modulated RT (IMRT) is a technique that relies upon software and modification of standard linear accelerator output to vary the radiation intensity across each treatment field. IMRT provides particular advantages when the target is juxtaposed to radiation-sensitive structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of IMRT in the treatment of malignant gliomas has become increasingly prevalent as it may decrease radiation-related adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/20\">",
"     20",
"    </a>",
"    ]. IMRT can also be used to escalate doses to the tumor, but there are no proven benefits to delivering doses beyond 60 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most appropriate application of IMRT in the brain will likely be when the radiation target abuts radiation-sensitive structures such as the eyes, optic nerves, optic chiasm, or brainstem. The disadvantages of IMRT include increased radiation scattering to surrounding nontarget tissues and the complexity of radiation planning, which requires adaptation of the hardware of linear accelerators, skilled physicist support, and increased delivery time for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reirradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous exposure to radiation of any dose is a known risk factor for the subsequent development of both benign and malignant brain tumors, including gliomas. Treatment of gliomas in patients with a history of prior cranial irradiation is a particular concern, because of the increase risk of late radiation-related side effects, including neurocognitive deficits and radiation necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for brain tumors\", section on 'Ionizing radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The survival benefit and safety of reirradiation as a component of therapy in glioma patients with prior cranial irradiation was supported by a review of the literature that identified a total of 92 cases of radiation-induced glioma, of which 35 underwent reirradiation to a median dose of 50 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/22\">",
"     22",
"    </a>",
"    ]. The one- and two-year survival rates were increased compared to the 57 patients who were not reirradiated (59 versus 15 and 21 versus 3 percent, respectively).",
"   </p>",
"   <p>",
"    In general, partial brain reirradiation to therapeutic doses for gliomas is considered acceptable with at least a five-year interval between radiation exposures. The median time between initial RT and occurrence of second tumor in this study was nine years for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/22\">",
"     22",
"    </a>",
"    ]. The interval time for the subset of patients who did undergo reirradiation was not specified but presumed to be well over five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other RT techniques have been evaluated in patients with malignant glioma, but do not have an established role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery uses three-dimensional planning techniques to precisely deliver narrowly collimated beams of ionizing radiation in a single high-dose fraction to small (&lt;4 cm) intracranial targets. When this approach is divided into several factions it is called stereotactic radiotherapy. The rationale, biology, and techniques for stereotactic radiosurgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery has been used to boost fractionated RT for the treatment of newly diagnosed GBM following either biopsy or resection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Results from observational studies have been mixed and are difficult to interpret because of patient selection bias [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Radiation Therapy Oncology Group (RTOG) was unable to demonstrate a benefit from adjuvant SRS in a phase III trial, in which 203 patients were randomly assigned to stereotactic radiosurgery followed by involved field RT plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    or to immediate involved field RT plus carmustine. Median survival was similar on both arms of the study (13.6 and 13.5 months, respectively), as was survival at two and three years (21 versus 19 percent and 9 versus 13 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Interstitial brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial brachytherapy uses the intraoperative placement of radioisotope seeds (most commonly iodine-125) into the tumor or resection cavity. These seeds release low-dose rate (LDR) irradiation for the duration of the life of the radioisotope [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Brachytherapy permits the delivery of a large radiation dose to the tumor volume, with rapid fall-off in surrounding tissues. Continuous rather than intermittent dose delivery decreases repair of sublethal damage and increases tumor susceptibility as cells progress into a sensitive phase of the cell cycle. The application of high-dose rate isotopes such as iridium-192 has also been tested.",
"   </p>",
"   <p>",
"    Despite the theoretical dosimetric and radiobiologic advantages of brachytherapy, randomized clinical trials have shown marginal or negligible benefit for the use of brachytherapy in the treatment of malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In the largest study, 299 patients with malignant gliomas were randomly assigned postoperatively to IFRT plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    with or without interstitial brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/34\">",
"     34",
"    </a>",
"    ]. The difference in median survival with the addition of brachytherapy was not statistically significant (68 versus 59 weeks without brachytherapy).",
"   </p>",
"   <p>",
"    Brachytherapy is technically complex, and its applicability is limited in patients with large or inaccessible tumors or involvement of eloquent brain locations. These constraints eliminate up to 75 percent of malignant glioma patients from consideration for brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/36\">",
"     36",
"    </a>",
"    ]. Interest in brachytherapy has waned with the use of 3D-CRT and stereotactic RT techniques to deliver a radiation boost, both of which offer dosimetric advantages similar to that of brachytherapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     '3D conformal RT'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Stereotactic radiosurgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Heavy particle RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Charged heavy particles (helium and neon ions), protons, and neutrons have been used alone and as a boost to conventional photon EBRT. The rationale for heavy particle RT is that these techniques may work better in the hypoxic microenvironment of malignant gliomas. In addition, heavy particle RT induces damage at more DNA sites, and tumor cells are less able to repair multiple damaged sites compared to the more sparse damage following photon RT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helium and neon ions &mdash; Heavy charged particles can be accelerated to energy levels that allow adequate tissue penetration to underlying, deep targets. The mass and charge of the neon and helium ions permit these particles to be stopped precisely in targeted tissue.",
"      <br/>",
"      <br/>",
"      No randomized trials have compared helium or neon ion therapy with photon irradiation. In a phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study, the median survival was 14 months in 17 patients with GBM treated with photon WBRT followed by helium or neon heavy particle boost, and the median survival in 11 patients with anaplastic astrocytoma was eight months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/40\">",
"       40",
"      </a>",
"      ]. Similar results were seen in a study of 15 patients with GBM treated with neon ion irradiation, with a median survival of 13 to 14 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/41\">",
"       41",
"      </a>",
"      ]. Overall, these data do not appear to be better than can be achieved with standard photon RT.",
"     </li>",
"     <li>",
"      Proton beam RT &mdash; Although proton beam RT is widely utilized for other tumors, there are limited data on its potential utility in GBM. In one series of 23 patients, proton RT resulted in a median survival of 20 months following surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/42\">",
"       42",
"      </a>",
"      ]. This study used a dose equivalent to 90 Gy. However, this dose escalation was associated with a high rate of tissue necrosis that led to progressive neurological symptoms and need for surgical intervention. Whereas the highly conformal radiation delivery with the use of protons can permit dose escalation, its potential application in treating GBM may be better suited to simply limiting RT-related side effects. These are questions that have yet to be addressed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H16#H16\">",
"       \"Complications of cranial irradiation\", section on 'Radiation necrosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation sensitizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation sensitizers are compounds that are given concurrently with RT in an effort to increase its therapeutic effect. Several classes of radiosensitizers have been studied in clinical trials but none of these have been approved for high grade gliomas or are in widespread use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360968\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of RT in elderly patients and potential modifications in dose and schedule are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=see_link&amp;anchor=H465193#H465193\">",
"     \"Management of malignant gliomas in elderly patients\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo a gross total resection of their malignant glioma have a high recurrence rate because of the infiltrative nature of these tumors. Clinical trials have shown that adjuvant chemotherapy can improve survival compared to surgery and postoperative RT without chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaplastic oligodendroglial tumors containing the",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    codeletion are markedly more sensitive to chemotherapy than oligodendroglial tumors not containing this chromosomal marker as well as nonoligodendroglial tumors. In this setting, chemotherapy in conjunction with postoperative RT is a common approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=see_link&amp;anchor=H175763196#H175763196\">",
"     \"Treatment of oligodendroglial tumors\", section on 'Postoperative therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant chemotherapy has been suggested as an alternative to adjuvant RT or adjuvant RT plus chemotherapy for grade III malignant gliomas. That data is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H13#H13\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Adjuvant chemotherapy with delayed RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RESPONSE AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient management decisions require an assessment of both initial response to treatment as well as subsequent evidence of progressive disease. Traditionally, this approach has used the Macdonald criteria which rely upon measurement of areas of contrast enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/43\">",
"     43",
"    </a>",
"    ]. New criteria have been proposed by the Response Assessment in Neuro-Oncology (RANO) working group to address problems in assessing patients with pseudoprogression or in assessing progressive disease in patients with nonenhancing lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no formal clinical trials that define the optimal frequency for follow-up after treatment. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that a repeat MRI should be obtained in patients with a malignant glioma about four weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/28/22978?source=see_link\">",
"       \"Patient information: Glioblastoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a newly-diagnosed malignant glioma (including both GBM and grade III malignant glioma), maximal surgical resection consistent with preservation of neurologic function is the initial step in management. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed glioblastoma (GBM), we recommend combined adjuvant chemoradiotherapy following surgery or biopsy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Involved field RT (typically 60 Gy) has replaced whole brain RT, because of its ability to minimize side effects to normal brain tissue and the likelihood of disease recurrence occurring locally. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a newly-diagnosed grade III glioma, we generally suggest adjuvant RT and chemotherapy following surgery or biopsy, using the same approach to RT and chemotherapy as in patients with GBM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of RT in elderly patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=see_link&amp;anchor=H465193#H465193\">",
"       \"Management of malignant gliomas in elderly patients\", section on 'Radiation therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=see_link&amp;anchor=H465209#H465209\">",
"       \"Management of malignant gliomas in elderly patients\", section on 'Contemporary randomized trials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      These recommendations for the management of patients with newly diagnosed glioblastoma are consistent with guidelines published by the American Association of Neurological Surgeons and the Congress of Neurological Surgeons [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4712/abstract/46-48\">",
"       46-48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/1\">",
"      Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/2\">",
"      Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978; 17:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/3\">",
"      Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/4\">",
"      Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988; 22:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/5\">",
"      Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/6\">",
"      Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/7\">",
"      Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988; :279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/8\">",
"      Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 1986; 13:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/9\">",
"      Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol 1991; 12:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/10\">",
"      Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/11\">",
"      Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/12\">",
"      Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986; 65:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/13\">",
"      Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991; 75:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/14\">",
"      Ten Haken RK, Thornton AF Jr, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol 1992; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/15\">",
"      Thornton AF Jr, Hegarty TJ, Ten Haken RK, et al. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991; 20:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/16\">",
"      Glatstein E, Lichter AS, Fraass BA, et al. The imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery. Int J Radiat Oncol Biol Phys 1985; 11:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/17\">",
"      Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998; 41:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/18\">",
"      Douglas JG, Stelzer KJ, Mankoff DA, et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006; 64:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/19\">",
"      Chang J, Thakur S, Perera G, et al. Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med Phys 2006; 33:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/20\">",
"      Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006; 64:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/21\">",
"      Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/22\">",
"      Paulino AC, Mai WY, Chintagumpala M, et al. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys 2008; 71:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/23\">",
"      Shrieve DC, Alexander E 3rd, Black PM, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999; 90:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/24\">",
"      Prisco FE, Weltman E, de Hanriot RM, Brandt RA. Radiosurgical boost for primary high-grade gliomas. J Neurooncol 2002; 57:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/25\">",
"      Masciopinto JE, Levin AB, Mehta MP, Rhode BS. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995; 82:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/26\">",
"      Nwokedi EC, DiBiase SJ, Jabbour S, et al. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 2002; 50:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/27\">",
"      Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006; 65:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/28\">",
"      Curran WJ Jr, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993; 11:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/29\">",
"      Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005; 63:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/30\">",
"      Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/31\">",
"      Marin LA, Smith CE, Langston MY, et al. Response of glioblastoma cell lines to low dose rate irradiation. Int J Radiat Oncol Biol Phys 1991; 21:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/32\">",
"      Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/33\">",
"      Koot RW, Maarouf M, Hulshof MC, et al. Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 2000; 88:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/34\">",
"      Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/35\">",
"      Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/36\">",
"      Wilson CB, Larson DA, Gutin PH. Radiosurgery: a new application? J Clin Oncol 1992; 10:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/37\">",
"      Cohen L, Awschalom M. Fast neutron radiation therapy. Annu Rev Biophys Bioeng 1982; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/38\">",
"      Cohen L, Hendrickson FR, Kurup PD, et al. Clinical evaluation of neutron beam therapy. Current results and prospects, 1983. Cancer 1985; 55:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/39\">",
"      Griffin TW, Davis R, Laramore G, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983; 6:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/40\">",
"      Castro JR, Saunders WM, Austin-Seymour MM, et al. A phase I-II trial of heavy charged particle irradiation of malignant glioma of the brain: a Northern California Oncology Group Study. Int J Radiat Oncol Biol Phys 1985; 11:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/41\">",
"      Castro JR, Phillips TL, Prados M, et al. Neon heavy charged particle radiotherapy of glioblastoma of the brain. Int J Radiat Oncol Biol Phys 1997; 38:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/42\">",
"      Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999; 91:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/43\">",
"      Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/44\">",
"      Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/46\">",
"      Fadul CE, Wen PY, Kim L, Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 2008; 89:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/47\">",
"      Buatti J, Ryken TC, Smith MC, et al. Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 2008; 89:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4712/abstract/48\">",
"      Ryken TC, Frankel B, Julien T, Olson JJ. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol 2008; 89:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5225 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4712=[""].join("\n");
var outline_f4_38_4712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Survival benefit from RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Involved field radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      3D conformal RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intensity-modulated RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reirradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Interstitial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Heavy particle RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation sensitizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360968\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ASSESSMENT OF RESPONSE AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=related_link\">",
"      Management of malignant gliomas in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/28/22978?source=related_link\">",
"      Patient information: Glioblastoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=related_link\">",
"      Treatment of oligodendroglial tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4713="Staging and prognosis of mycosis fungoides and Szary syndrome";
var content_f4_38_4713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Youn H Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4713/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4713/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13601333\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycosis fungoides (MF) and S&eacute;zary syndrome (SS) are the most common subtypes of cutaneous T cell lymphoma (CTCL).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MF is a mature T cell non-Hodgkin lymphoma with presentation in the skin but with potential involvement of the nodes, blood, and viscera. Skin lesions include patches or plaques that may be localized or widespread, tumors, and erythroderma.",
"     </li>",
"     <li>",
"      SS is a distinctive erythrodermic CTCL with a leukemic involvement of malignant T cells clonally matching that in the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This group of disorders differs from other primary CTCLs by virtue of unique clinical features and histopathology. This topic review will discuss the staging, response criteria, and prognosis of MF and SS. The diagnosis and management of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118879\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard staging classification system for MF and SS is the TNMB system, which is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B) (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"UTD.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/1\">",
"     1",
"    </a>",
"    ]. The standard staging evaluation includes a careful examination of the skin (especially the scalp, palms, soles, and perineum) with skin biopsy, a complete blood count with S&eacute;zary cell analysis, screening chemistries including lactate dehydrogenase, and a chest x-ray (",
"    <a class=\"graphic graphic_table graphicRef75528 \" href=\"UTD.htm?18/6/18541\">",
"     table 2",
"    </a>",
"    ). Lymph node biopsies, not fine needle aspirations, are obtained if lymphadenopathy is present, since lymph node involvement affects both the stage and prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118886\">",
"    <span class=\"h2\">",
"     Skin evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122851\">",
"    <span class=\"h3\">",
"     Total body skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should undergo a total body skin examination (TBSE). The basic tenets of the whole-body skin examination are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examine the face and rest of the head and neck while the patient is sitting on the examination table.",
"     </li>",
"     <li>",
"      Examine the scalp.",
"     </li>",
"     <li>",
"      Examine all surfaces of the arms and hands.",
"     </li>",
"     <li>",
"      Ask the patient to lie down on",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      back for viewing the chest, abdomen, anterior thighs, perineum, anterior legs, dorsal feet, soles, and toe webs.",
"     </li>",
"     <li>",
"      Ask the patient to turn over. Examine the calves, posterior thighs, buttocks, and back.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The upper body could also be examined when the patient is sitting or standing. Regardless of the specific order of examination, TBSE should be standardized to insure completeness. When performing the TBSE, skin lesions are classified as patches, papules, plaques, or tumors according to the following definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patch &mdash; Any size lesion without induration or significant elevation above the surrounding uninvolved skin; poikiloderma may be present",
"     </li>",
"     <li>",
"      Plaque &mdash; Any size lesion that is elevated or indurated; crusting, ulceration, or poikiloderma may be present",
"     </li>",
"     <li>",
"      Tumor &mdash; Any solid or nodular lesions &ge;1 cm in diameter with evidence of deep infiltration in the skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertical growth",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122858\">",
"    <span class=\"h3\">",
"     Percent body surface area estimates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percentage of body surface area (BSA) involved by each type of lesion (eg, patch, plaque, tumor) should be estimated and recorded. Areas of alopecia are included in the BSA only if they are thought to be manifestations of disease, such as seen in patients with the folliculotropic variant of MF. If tumors are present, the total number, aggregate volume, size of the largest lesion, and involved body regions should be noted. Methods of measuring percentage BSA have been adapted from studies in patients with burns. BSA measurement in patients with burns is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link&amp;anchor=H16#H16\">",
"     \"Classification of burns\", section on 'Percent body surface area estimates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several methods are available to calculate the estimated percentage BSA involved. Smaller areas are most easily measured using the &ldquo;palm method&rdquo;, while larger areas are more easily measured using an estimation of BSA for specific body regions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The &ldquo;palm method&rdquo; &mdash; This method uses the palm of the patient's hand, excluding the fingers, as approximately 0.5 percent of total BSA and the entire palmar surface including fingers as 1 percent BSA in children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The &ldquo;rule of nines&rdquo; &mdash; The &ldquo;rule of nines&rdquo; is a quick method of estimating total BSA in adults in which each leg represents 18 percent total BSA, each arm represents 9 percent total BSA, the anterior and posterior trunk each represent 18 percent total BSA, and the head represents 9 percent total BSA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Lund-Browder chart &mdash; The Lund-Browder chart is the most accurate method for estimating percentage total BSA for both adults and children and takes into account the relative percentage of body surface area affected by growth (",
"      <a class=\"graphic graphic_figure graphicRef71190 \" href=\"UTD.htm?42/35/43575\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The percent of total BSA involved may be underestimated in women with involvement of the anterior trunk and large breasts. For every increase in cup size, the total BSA of a woman&rsquo;s anterior trunk increases by a factor of 0.1, relative to the posterior trunk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122865\">",
"    <span class=\"h3\">",
"     Disease severity estimates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoring systems have been developed to measure disease severity. Global scoring systems provide an objective measure of overall disease burden designed to assess the efficacy of a systemic therapy (eg, systemic retinoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    ). In contrast, a local skin scoring system provides a measure of the severity of an individual lesion and may be used to assess the efficacy of a local therapy (eg, topical corticosteroids). Global scoring systems include the severity weight assessment tool (SWAT) score and the modified SWAT (mSWAT) score; these measures may also be used to score individual skin lesions. Alternatively, the Composite Assessment of Index Lesion Severity (CAILS) score can be used for local skin scoring.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       SWAT and mSWAT",
"      </strong>",
"      &mdash; The SWAT and the mSWAT scores provide a global measure of disease severity by incorporating information regarding the percentage of total body surface area (BSA) involved by each type of skin lesion (",
"      <a class=\"graphic graphic_table graphicRef83963 \" href=\"UTD.htm?24/27/25021\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]. The percentage of involved BSA is then multiplied by a weight according to lesion type (ie, patch=1, plaque=2, tumor=3 or 4). These scores were designed to reflect the increase in dermal infiltrate thickness (and disease burden) with tumor versus plaque versus patch lesions. Individual lesions can also be scored using the SWAT and mSWAT criteria by multiplying the percentage of total BSA involved by an individual lesion and multiplying by the weight assigned to the lesion type.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       CAILS",
"      </strong>",
"      &mdash; The CAILS score is used to assess disease severity of an individual lesion. This method rates each of five characteristics (ie, erythema, scaling, plaque elevation, hypo- or hyperpigmentation if reflective of active disease, and size) on a scale from 1 to 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/13\">",
"       13",
"      </a>",
"      ]. The CAILS score is a sum of the rating given to each of these criteria (",
"      <a class=\"graphic graphic_table graphicRef83962 \" href=\"UTD.htm?38/17/39196\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Widespread use of each of these scoring systems in clinical practice is limited by substantial interobserver variability due the subjectivity of many of the measures. Ideally, the same clinician should be responsible for determining serial scores for each patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118893\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of imaging studies used for the staging of MF and SS is dependent upon the degree of skin, lymph node, and blood involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/2\">",
"     2",
"    </a>",
"    ]. As always, care should be taken to limit radiation exposure, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. In asymptomatic, otherwise healthy patients with apparently early stage (T",
"    <sub>",
"     1",
"    </sub>",
"    N",
"    <sub>",
"     0",
"    </sub>",
"    B",
"    <sub>",
"     0",
"    </sub>",
"    or T",
"    <sub>",
"     2",
"    </sub>",
"    N",
"    <sub>",
"     0",
"    </sub>",
"    B",
"    <sub>",
"     0",
"    </sub>",
"    ) MF, imaging studies may be limited to a chest radiograph. Further imaging is reserved for patients with &ge;T",
"    <sub>",
"     2",
"    </sub>",
"    skin lesions, palpable adenopathy, abnormal laboratory studies, or pathology consistent with large cell transformed MF or folliculotropic MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/14\">",
"     14",
"    </a>",
"    ]. For these patients, we perform a computed tomography (CT) scan of the neck, chest, abdomen, and pelvis with or without an integrated positron emission tomography (PET) scan. Magnetic resonance imaging (MRI) can be substituted for patients who are unable to safely undergo CT.",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the sensitivity and specificity of CT and PET scans in the staging of MF and SS. Visceral disease is highly unusual in the absence of significant blood or nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In an initial study of 62 patients with newly diagnosed MF or SS, 85 percent of whom had apparently early stage disease, CT imaging did not improve upon staging with physical examination and routine lymph node biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/15\">",
"     15",
"    </a>",
"    ]. In a subsequent case series of 13 patients with MF or SS at risk for secondary lymph node involvement, integrated whole body",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning was more sensitive in detecting lymph node involvement than was physical examination or CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/16\">",
"     16",
"    </a>",
"    ]. The intensity of PET activity loosely correlated with the histologic grade of the removed nodes, and was highest in those with large cell transformation.",
"   </p>",
"   <p>",
"    Suspected sites of visceral involvement other than the liver or spleen must be confirmed by histologic evaluation, when possible. Given the potential morbidity associated with biopsy, imaging studies are sufficient to demonstrate liver or spleen involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118900\">",
"    <span class=\"h2\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with MF or SS require lymph node biopsy as part of staging. Lymph node biopsy is reserved for patients with palpable lymphadenopathy. If present, a lymph node 1.5 cm or greater in diameter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a lymph node that is firm, irregular, clustered, or fixed should undergo excisional biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/1\">",
"     1",
"    </a>",
"    ]. If there is more than one suspicious lymph node, biopsy preference is given to lymph nodes draining an area of involved skin or the node with the highest standardized uptake value on FDG-PET scan. If there are multiple suspicious nodes that otherwise seem equivalent by those measures, the order of biopsy preference is: cervical, axillary, and then inguinal.",
"   </p>",
"   <p>",
"    The degree of lymph node replacement by atypical cells can be described as a grade that has prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/18\">",
"     18",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ISCL/EORTC",
"    </span>",
"    lymph node classification system reflects the degree of infiltration by these atypical cells in clinically enlarged lymph nodes. Lymph nodes are classified as N",
"    <sub>",
"     1",
"    </sub>",
"    through N",
"    <sub>",
"     3",
"    </sub>",
"    , ranging from \"no atypical lymphocytes\" of N",
"    <sub>",
"     0",
"    </sub>",
"    to \"complete replacement of nodal architecture by atypical lymphocytes or frank neoplastic cells\" of N",
"    <sub>",
"     3",
"    </sub>",
"    . These nodal staging systems are then further subclassified by the absence (a) or presence (b) of clonal cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118907\">",
"    <span class=\"h2\">",
"     Bone marrow aspirate and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant bone marrow involvement with an infiltrative histologic pattern is most often present in patients who meet the clinical criteria for S&eacute;zary syndrome. These patients have readily detectable S&eacute;zary cells in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/19\">",
"     19",
"    </a>",
"    ]. As a result, bone marrow biopsy is not routinely employed as part of the initial staging procedure for patients with MF. However, it may be useful in selected cases to document visceral disease if marrow involvement is suspected, such as in the setting of B",
"    <sub>",
"     2",
"    </sub>",
"    blood involvement or in patients with an unexplained hematologic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118914\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931806\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main predictor of outcomes in MF is the overall clinical stage as defined by the TNMB criteria described above (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"UTD.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). Of the factors that go into determining the clinical stage, the extent and type of skin involvement (T-stage) (",
"    <a class=\"graphic graphic_figure graphicRef54376 \" href=\"UTD.htm?43/11/44221\">",
"     figure 2",
"    </a>",
"    ) and presence of extracutaneous disease (",
"    <a class=\"graphic graphic_figure graphicRef74471 \" href=\"UTD.htm?31/20/32077\">",
"     figure 3",
"    </a>",
"    ) are the most important indicators predictive of survival in patients with MF. Consistent with this, patients with S&eacute;zary syndrome (SS) have a worse prognosis than erythrodermic patients with MF who do not have the other findings of the SS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/20\">",
"     20",
"    </a>",
"    ]. Other factors associated with a worse prognosis include transformation to large cell histology and the folliculotropic variant of MF.",
"   </p>",
"   <p>",
"    For patients presenting with skin only disease, the risk of progression to extracutaneous disease increases with T-stage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, in 434 patients initially presenting with skin involvement only, the risk for progression to extracutaneous disease at 20 years was zero, 10, 36, and 41 percent for patients presenting with T",
"    <sub>",
"     1",
"    </sub>",
"    , T",
"    <sub>",
"     2",
"    </sub>",
"    , T",
"    <sub>",
"     3",
"    </sub>",
"    , and T",
"    <sub>",
"     4",
"    </sub>",
"    involvement, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another cohort of 1502 patients with",
"    <span class=\"nowrap\">",
"     MF/SS,",
"    </span>",
"    disease progression occurred in 34 percent, and 26 percent of patients died due to",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"     22",
"    </a>",
"    ]. A significant difference in survival and risk of disease progression was noted for patients with early-stage disease having patches alone",
"    <span class=\"nowrap\">",
"     (T",
"     <sub>",
"      1a",
"     </sub>",
"     /T",
"     <sub>",
"      2a",
"     </sub>",
"     )",
"    </span>",
"    compared with those having patches and plaques",
"    <span class=\"nowrap\">",
"     (T",
"     <sub>",
"      1b",
"     </sub>",
"     /T",
"     <sub>",
"      2b",
"     </sub>",
"     ).",
"    </span>",
"    On multivariate analysis, the following factors were associated with survival",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease progression (",
"    <a class=\"graphic graphic_figure graphicRef83542 \" href=\"UTD.htm?34/44/35535\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced skin (T) stage, the presence in peripheral blood of the tumor clone without S&eacute;zary cells (B",
"      <sub>",
"       0b",
"      </sub>",
"      ), increased lactate dehydrogenase (LDH), and folliculotropic MF were independent predictors of poor survival and increased risk of disease progression.",
"     </li>",
"     <li>",
"      Large-cell transformation and tumor distribution were independent predictors of increased risk of disease progression only.",
"     </li>",
"     <li>",
"      N, M, and B stages; age; male sex; and poikilodermatous MF were predictors of poor survival, but not associated with risk of disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with lymph node biopsies showing dermatopathic changes or only a small number of atypical cells (histologic grade LN-1 or LN-2) have a five-year survival of 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/18\">",
"     18",
"    </a>",
"    ]. Those patients with large clusters of paracortical atypical cells (LN-3) have a five-year survival of 30 percent, while those with effaced nodes (LN-4) have a five-year survival of only 15 percent. Actual lymph node involvement with MF (N-stage 2 or 3 of the TNMB classification, overall stage IVA) correlates with histologic grade of LN-3 or -4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a significant number of S&eacute;zary cells in the peripheral blood (B",
"    <sub>",
"     1",
"    </sub>",
"    or B",
"    <sub>",
"     2",
"    </sub>",
"    ) generally correlates with more advanced T-stage (usually T",
"    <sub>",
"     4",
"    </sub>",
"    ) and the presence of extracutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As an example, in an analysis of 1263 patients with MF or S&eacute;zary syndrome, which included 199 patients with B",
"    <sub>",
"     1",
"    </sub>",
"    or B",
"    <sub>",
"     2",
"    </sub>",
"    disease, patients with a significant number of S&eacute;zary cells in the peripheral blood had a worse overall and disease-specific survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/23\">",
"     23",
"    </a>",
"    ]. The survival of patients with B",
"    <sub>",
"     2",
"    </sub>",
"    disease was worse than that of patients with B",
"    <sub>",
"     1",
"    </sub>",
"    disease (median overall survival 4.64 years versus not reached; hazard ratio 0.11, 95% CI 0.01 to 0.80).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22447869\">",
"    <span class=\"h2\">",
"     Prognosis by stage",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118921\">",
"    <span class=\"h3\">",
"     Stage IA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with limited",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    (T",
"    <sub>",
"     1",
"    </sub>",
"    , overall stage IA) disease have an excellent prognosis with an overall long-term life expectancy that is similar to an age-, sex-, and race-matched control population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22,23,25,26\">",
"     22,23,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter retrospective analysis of patients with MF followed for a median of 14.5 years, 412 of 552 (75 percent) patients with stage IA disease at diagnosis did not progress beyond this stage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/27\">",
"       27",
"      </a>",
"      ]. Five- and 10-year overall survival rates were 97 and 93 percent, respectively.",
"     </li>",
"     <li>",
"      Another study conducted out of the United Kingdom included 438 patients with stage IA disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ]. Median survival was 35.5 years with rates of disease progression at 5, 10, and 20 years of 8, 12, and 18 percent, respectively.",
"     </li>",
"     <li>",
"      According to a retrospective study of 122 stage IA patients at Stanford, the median survival was not reached at 33 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/25\">",
"       25",
"      </a>",
"      ]. Nearly all patients with stage IA disease who died did so from causes other than MF. Furthermore, only 9 percent of treated patients at this stage progressed to a more advanced stage of disease. Patients who did progress had a lower complete response rate to initial therapy and an older mean age than did other patients with stage IA disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of stage IA MF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Stage IA disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118928\">",
"    <span class=\"h3\">",
"     Stages IB and IIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with generalized",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease without evidence of extracutaneous involvement (T",
"    <sub>",
"     2",
"    </sub>",
"    , stage IB or stage IIA) have a median survival greater than 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22,23,28\">",
"     22,23,28",
"    </a>",
"    ]. Patients with T",
"    <sub>",
"     2",
"    </sub>",
"    disease have a greater likelihood of disease progression (24 percent) than patients with T",
"    <sub>",
"     1",
"    </sub>",
"    disease, and nearly 20 percent die of causes related to MF. Overall survivals of patients with stages IB and IIA disease are not significantly different.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 583 patients with stage IB MF and 40 patients with stage IIA MF reported median survival rates of 22 and 16 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ]. The two patient groups had similar rates of disease progression at five (21 and 17 percent), 10 (38 and 33 percent), and 20 (47 and 41 percent) years.",
"     </li>",
"     <li>",
"      In a multicenter retrospective analysis of patients with MF followed for a median of 14.5 years, 396 of 556 (71 percent) patients with stage IB disease and 73 of 122 (60 percent) patients with stage IIA disease at diagnosis did not progress beyond their initial stage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/27\">",
"       27",
"      </a>",
"      ]. Five- and 10-year overall survival rates were 91 and 86 percent for stage IB and 79 and 72 percent for stage IIA, respectively. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of stage IB and IIA MF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Stage IB/IIA disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118935\">",
"    <span class=\"h3\">",
"     Stages IIB and III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cutaneous tumors (T",
"    <sub>",
"     3",
"    </sub>",
"    , stage IIB) and generalized erythroderma (T",
"    <sub>",
"     4",
"    </sub>",
"    , stage III) without extracutaneous disease have median survivals of approximately 3.5 to 6 years (",
"    <a class=\"graphic graphic_figure graphicRef54376 \" href=\"UTD.htm?43/11/44221\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22,23,29\">",
"     22,23,29",
"    </a>",
"    ]. The majority of these patients will die of MF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter retrospective analysis of patients with MF followed for a median of 14.5 years, disease progression occurred in 34 of 78 (44 percent) patients with IIB disease, 32 of 82 (39 percent) patients with stage IIIA disease, and 6 of 11 (55 percent) with stage IIIB disease at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/27\">",
"       27",
"      </a>",
"      ]. The five- and 10-year overall survival rates did not differ among these three groups and were approximately 70 and 50 percent, respectively.",
"     </li>",
"     <li>",
"      A retrospective study of patients with stage IIB (167 patients), IIIA (100 patients), or IIIB (56 patients) MF treated at a single institution reported median survival rates of 4.7, 4.7, and 3.4 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ]. The corresponding risk of disease progression at five years was 48, 53, and 82 percent, respectively.",
"     </li>",
"     <li>",
"      In another single-center, retrospective study, the 136 patients with T3 MF had a median overall survival of 5.96 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long term outcome in patients with erythroderma (T",
"    <sub>",
"     4",
"    </sub>",
"    ) is variable and appears to be at least partially dependent upon patient age at presentation, overall stage, peripheral blood involvement, and the duration of symptoms prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. In a retrospective study of 106 patients with MF, patients with zero, one, or more than one unfavorable prognostic factor (ie, age &gt;65 years, peripheral blood involvement, stage IV disease, duration of symptoms &lt;10 years) had median survivals of 10.2, 3.7, and 1.5 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of stage IIB and III MF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118942\">",
"    <span class=\"h3\">",
"     Stages IVA and IVB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extracutaneous disease at presentation involving either lymph nodes (stage IVA) or viscera (stage IVB) have a poor prognosis with median survival of less than four years from the date of first treatment (",
"    <a class=\"graphic graphic_figure graphicRef74471 \" href=\"UTD.htm?31/20/32077\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/21,22,27\">",
"     21,22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single-center retrospective analysis of patients with stage IVA1 (67 patients), IVA2 (37 patients), or IVB (14 patients) MF reported median survival rates of 3.8, 2.1, and 1.4 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"     22",
"    </a>",
"    ]. Corresponding rates of disease progression by five years were 62, 77, and 82 percent, respectively.",
"   </p>",
"   <p>",
"    The treatment of stage IV MF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118949\">",
"    <span class=\"h2\">",
"     Transformation to large cell histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with plaque-type or erythrodermic MF may develop cutaneous tumors with large cell histology. By definition, such large cells are at least four times greater in size than a small lymphocyte. The transformation to large cell histology is diagnosed when more than 25 percent of the total lymphoid infiltrate is made up of these large cells or if these cells create microscopic nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Incidence rates of transformation in patients with MF have ranged from approximately 10 to 25 percent; with variation according to the stage at presentation.",
"   </p>",
"   <p>",
"    Clinical findings with large cell transformation are variable, but may include new, solitary nodules within a long-standing patch or plaque; the rapid development of multiple pink scattered nodules without spontaneous resolution; or new or enlarging tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/33\">",
"     33",
"    </a>",
"    ]. Clinicians should maintain a low threshold for biopsy of new papules, nodules, and or tumors that develop in patients with MF if it is believed that the findings might result in a change of therapy.",
"   </p>",
"   <p>",
"    The following is a survey of reports on the transformation of MF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 419 patients with MF reported that 45 were found to have transformed at a median time after diagnosis of 6.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/34\">",
"       34",
"      </a>",
"      ]. On multivariate analysis, only age &ge;60 and extracutaneous spread were associated with a poor prognosis.",
"     </li>",
"     <li>",
"      A retrospective analysis of 297 patients reported that the rate of transformation ranged from 1.4 percent for patients with stage IA through IIA disease to 67 percent in patients with stage IVB disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single-institution study of 70 patients with large cell transformation reported a median survival of 8.3 years and rates of disease progression at five, 10, and 20 years of 49, 75, and 87 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, the cumulative probability of transformation was 39 percent in 12 years, with a median time from diagnosis of MF to transformation of 12 months (range: zero to 128 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/31\">",
"       31",
"      </a>",
"      ]. The following observations were of interest:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The median survival from initial diagnosis of MF was 3 and 14 years for the transformed and untransformed patients, respectively.",
"     </li>",
"     <li>",
"      Transformation occurred in 14, 31, and 46 percent of patients with stage I to IIA disease, IIB to IV disease, and those with skin tumors (T",
"      <sub>",
"       3",
"      </sub>",
"      ), respectively.",
"     </li>",
"     <li>",
"      Elevation of serum beta-2 microglobulin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lactate dehydrogenase was predictive for transformation.",
"     </li>",
"     <li>",
"      Median survival from transformation was 19 months; transformation &lt;2 years from the initial diagnosis of MF and advanced stage were associated with inferior survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with large cell transformation have heterogeneous outcomes with some experiencing rapid deterioration and others having a more indolent clinical course. A retrospective study of 100 patients with transformed MF reported a median survival after transformation of 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/36\">",
"     36",
"    </a>",
"    ]. Disease-specific survival (DSS) rates at two, five, and 10 years were 62, 38, and 36 percent, respectively. Corresponding rates of overall survival were 57, 33, and 24 percent. The following four clinicopathologic features were independently predictive of a worse outcome: generalized skin lesions, negative staining for CD30, folliculotropic MF, and extracutaneous disease. Using these prognostic factors, patients could be stratified into two cohorts with significantly different disease trajectories. DSS was approximately 60 percent in patients with zero or one unfavorable prognostic factor. In comparison, DSS was less than 20 percent in patients with two or more unfavorable prognostic factors. Further studies are needed to determine whether this prognostic information may be used to alter the treatment approach for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118956\">",
"    <span class=\"h2\">",
"     Folliculotropic variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folliculotropic MF is a variant of MF characterized by infiltration of follicles. Data regarding the prognosis of patients with folliculotropic MF are difficult to ascertain because it is not common. In most, but not all studies, folliculotropic MF has been associated with a markedly worse prognosis when compared with other MF variants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/23,37-43\">",
"     23,37-43",
"    </a>",
"    ]. For this reason, a more aggressive treatment approach is often recommended for patients with folliculotropic MF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies illustrate the clinical features and outcomes of folliculotropic MF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter retrospective cohort analysis examined the outcomes of 51 patients with folliculotropic MF and 158 patients with classic epidermotropic MF [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/40\">",
"       40",
"      </a>",
"      ]. Of the patients with folliculotropic MF, the majority of patients had skin only lesions (88 percent) while a few had enlarged but uninvolved nodes (8 percent), involved nodes (2 percent), or visceral disease (2 percent). At a median follow-up of 48 months, 39 percent had developed extracutaneous disease. The five- and 10-year disease-specific survival rates were 68 and 26 percent, respectively.",
"     </li>",
"     <li>",
"      A single institution retrospective study of 50 patients with folliculotropic MF reported one and five-year overall survival rates of 96 and 62 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/43\">",
"       43",
"      </a>",
"      ]. Review of these cases and 186 additional patients found by systematic review noted that folliculotropic MF was more common in males; frequently presented with pruritic lesions (73 percent) involving the head, neck, and trunk; and demonstrated follicular mucinosis (69 percent) and epidermotropism (37 percent) on biopsy.",
"     </li>",
"     <li>",
"      A study from the United Kingdom of 1502 patients with MF or S&eacute;zary syndrome included 189 patients with the folliculotropic variant (13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ]. When compared with the group as a whole, patients with folliculotropic variant MF demonstrated a significantly higher risk of disease progression (relative risk 2.11), but similar rates of overall and disease-specific survival.",
"     </li>",
"     <li>",
"      A prospective study from MD Anderson Cancer Center of 1263 patients with MF or S&eacute;zary syndrome identified 44 patients with folliculotropic variant (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/23\">",
"       23",
"      </a>",
"      ]. Folliculotropic variant was not an independent predictor of progression-free, disease-specific, or overall survival. The low number of patients with folliculotropic variant in this sample is unusual and questions whether all patients with folliculotropic variant were captured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118963\">",
"    <span class=\"h2\">",
"     Other prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors have been shown to add significant prognostic information to that provided by the TNMB staging system described above. It is not clear as of yet how they might be incorporated into clinical use.",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of a high percentage of activated CD8+ T cells infiltrating the lesions of MF may confer a better prognosis, perhaps through an antitumor effect [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. In one study of patients with MF in the plaque and tumor stages, actuarial survival at five years was 96 and 61 percent for those with &gt;17 or &le;17 percent of CD8+ T cells, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Another study noted that patients with poikilodermatous MF, hypopigmented MF, and MF associated with lymphomatoid papulosis had a significantly better outcome with superior survival and a lower rate of progression [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A single institution retrospective analysis of 97 patients with MF identified an elevated erythrocyte sedimentation rate (ESR) as an independent marker of poor outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/46\">",
"       46",
"      </a>",
"      ]. Five-year disease-specific survival was 100 percent for those with normal ESR, compared with 53 percent for those with ESR elevated above the normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3185075\">",
"    <span class=\"h1\">",
"     RESPONSE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific evaluation performed to assess response to therapy differs depending upon whether the patient is enrolled in a therapeutic research protocol or is being treated in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For those treated in clinical practice, evaluation of the response to treatment should always include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete skin examination including a determination of the type of skin lesions and the estimated percentage of total body surface area involved by patches, plaques, and tumor lesions.",
"     </li>",
"     <li>",
"      Survey of the lymph nodes and assessment for organomegaly.",
"     </li>",
"     <li>",
"      Complete blood count with manual differential and assessment for S&eacute;zary cells.",
"     </li>",
"     <li>",
"      Repeat imaging studies that were abnormal previously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients treated as part of a research protocol, the evaluation includes all that was listed above. In addition, the evaluation often includes more detailed imaging studies (eg, CT scans) and measures of disease severity (eg, mSWAT score).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3185082\">",
"    <span class=\"h1\">",
"     RESPONSE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus statement regarding response criteria has been published by the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer (",
"    <a class=\"graphic graphic_table graphicRef87757 \" href=\"UTD.htm?31/55/32638\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4713/abstract/2\">",
"     2",
"    </a>",
"    ]. All responses should be documented to last at least four weeks. Similarly, in cases of clinical uncertainty, progressive disease and relapse should be reevaluated after four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118970\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycosis fungoides (MF) is an extranodal indolent non-Hodgkin lymphoma of T cell origin that is characterized by skin involvement. S&eacute;zary syndrome (SS) is a more aggressive leukemic variant of cutaneous T cell lymphoma in which a significant number of circulating malignant (S&eacute;zary) cells are observed in the peripheral blood.",
"     </li>",
"     <li>",
"      The standard staging system for MF and SS is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B) (",
"      <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"UTD.htm?6/60/7119\">",
"       table 1A-B",
"      </a>",
"      ). This includes a careful skin examination with biopsy, a complete blood count with S&eacute;zary cell analysis, screening chemistries, and chest x-ray (",
"      <a class=\"graphic graphic_table graphicRef75528 \" href=\"UTD.htm?18/6/18541\">",
"       table 2",
"      </a>",
"      ). Computed tomography with or without positron emission tomography is indicated for patients with more advanced clinical disease. Lymph node biopsies are obtained if lymphadenopathy is present. Bone marrow biopsy may be useful in selected cases to document visceral disease. (See",
"      <a class=\"local\" href=\"#H1118879\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As expected, the prognosis of MF and SS varies with disease stage. Patients with limited",
"      <span class=\"nowrap\">",
"       patch/plaque",
"      </span>",
"      disease have an excellent prognosis with an overall long-term life expectancy that is similar to an age-, sex-, and race-matched control population. Patients with generalized",
"      <span class=\"nowrap\">",
"       patch/plaque",
"      </span>",
"      disease also have a relatively good prognosis with a median survival greater than 10 years. Median survivals drop to approximately four years in patients with cutaneous tumors or generalized erythroderma. Patients with extracutaneous disease at presentation involving either lymph nodes or viscera have a median survival of 13 months. (See",
"      <a class=\"local\" href=\"#H22447869\">",
"       'Prognosis by stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with tumors that demonstrate transformation to a CD30+ large cell lymphoma and patients with folliculotropic MF do markedly worse than patients with other variants of MF. For this reason, a more aggressive treatment approach is often recommended for patients with folliculotropic MF or large cell transformation. (See",
"      <a class=\"local\" href=\"#H1118949\">",
"       'Transformation to large cell histology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1118956\">",
"       'Folliculotropic variant'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/1\">",
"      Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/2\">",
"      Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/3\">",
"      Perry RJ, Moore CA, Morgan BD, Plummer DL. Determining the approximate area of a burn: an inconsistency investigated and re-evaluated. BMJ 1996; 312:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/4\">",
"      Sheridan RL, Petras L, Basha G, et al. Planimetry study of the percent of body surface represented by the hand and palm: sizing irregular burns is more accurately done with the palm. J Burn Care Rehabil 1995; 16:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/5\">",
"      Nagel TR, Schunk JE. Using the hand to estimate the surface area of a burn in children. Pediatr Emerg Care 1997; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/6\">",
"      Monafo WW. Initial management of burns. N Engl J Med 1996; 335:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/7\">",
"      Wachtel TL, Berry CC, Wachtel EE, Frank HA. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns 2000; 26:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/8\">",
"      Mertens DM, Jenkins ME, Warden GD. Outpatient burn management. Nurs Clin North Am 1997; 32:343.",
"     </a>",
"    </li>",
"    <li>",
"     Woodson, LC, Sherwood, ER, Aarsland, A, et, al. Anesthesia for burned patients. In: Total Burn Care, 3rd edition, Herndon, DN (Eds), Saunders Elsevier, Philadelphia 2007. p.196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/10\">",
"      Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obstet 1944; 79:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/11\">",
"      Hidvegi N, Nduka C, Myers S, Dziewulski P. Estimation of breast burn size. Plast Reconstr Surg 2004; 113:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/12\">",
"      Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002; 138:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/13\">",
"      Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137:581.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on May 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/15\">",
"      Kulin PA, Marglin SI, Shuman WP, et al. Diagnostic imaging in the initial staging of mycosis fungoides and S&eacute;zary syndrome. Arch Dermatol 1990; 126:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/16\">",
"      Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/17\">",
"      Kamstrup MR, Gniadecki R, Friberg L. Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma. Arch Dermatol 2012; 148:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/18\">",
"      Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/S&eacute;zary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/19\">",
"      Salhany KE, Greer JP, Cousar JB, Collins RD. Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases. Am J Clin Pathol 1989; 92:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/20\">",
"      Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the S&eacute;zary syndrome. Arch Dermatol 1995; 131:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/21\">",
"      de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/22\">",
"      Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/S&eacute;zary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28:4730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/23\">",
"      Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and S&eacute;zary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18:5051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/24\">",
"      Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the S&eacute;zary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990; 14:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/25\">",
"      Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/26\">",
"      Ally MS, Pawade J, Tanaka M, et al. Solitary mycosis fungoides: a distinct clinicopathologic entity with a good prognosis: a series of 15 cases and literature review. J Am Acad Dermatol 2012; 67:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/27\">",
"      Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012; 118:5830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/28\">",
"      Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/29\">",
"      Kim YH, Hoppe RT. Mycosis fungoides and the S&eacute;zary syndrome. Semin Oncol 1999; 26:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/30\">",
"      Scarisbrick JJ, Whittaker S, Evans AV, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/31\">",
"      Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92:1150.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/33\">",
"      Herrmann JL, Hughey LC. Recognizing large-cell transformation of mycosis fungoides. J Am Acad Dermatol 2012; 67:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/34\">",
"      Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000; 95:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/35\">",
"      Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008; 112:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/36\">",
"      Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012; 119:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/37\">",
"      Klemke CD, Dippel E, Assaf C, et al. Follicular mycosis fungoides. Br J Dermatol 1999; 141:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/38\">",
"      Bonta MD, Tannous ZS, Demierre MF, et al. Rapidly progressing mycosis fungoides presenting as follicular mucinosis. J Am Acad Dermatol 2000; 43:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/39\">",
"      Gilliam AC, Lessin SR, Wilson DM, Salhany KE. Folliculotropic mycosis fungoides with large-cell transformation presenting as dissecting cellulitis of the scalp. J Cutan Pathol 1997; 24:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/40\">",
"      van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/41\">",
"      Kim SY. Follicular mycosis fungoides. Am J Dermatopathol 1985; 7:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/42\">",
"      Gerami P, Rosen S, Kuzel T, et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008; 144:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/43\">",
"      Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol 2010; 146:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/44\">",
"      Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/45\">",
"      Vermeer MH, van Doorn R, Dukers D, et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19:4322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4713/abstract/46\">",
"      Hallermann C, Niermann C, Fischer RJ, Schulze HJ. Erythrocyte sedimentation rate as an independent prognostic factor in mycosis fungoides. Br J Dermatol 2012; 166:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83281 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4713=[""].join("\n");
var outline_f4_38_4713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1118970\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13601333\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118879\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118886\">",
"      Skin evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4122851\">",
"      - Total body skin examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4122858\">",
"      - Percent body surface area estimates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4122865\">",
"      - Disease severity estimates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118893\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118900\">",
"      Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118907\">",
"      Bone marrow aspirate and biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118914\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931806\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22447869\">",
"      Prognosis by stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118921\">",
"      - Stage IA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118928\">",
"      - Stages IB and IIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118935\">",
"      - Stages IIB and III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118942\">",
"      - Stages IVA and IVB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118949\">",
"      Transformation to large cell histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118956\">",
"      Folliculotropic variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118963\">",
"      Other prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3185075\">",
"      RESPONSE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3185082\">",
"      RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118970\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/83281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83281|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/35/43575\" title=\"figure 1\">",
"      Burn class adult child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/11/44221\" title=\"figure 2\">",
"      MF prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/20/32077\" title=\"figure 3\">",
"      Survival advanced MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/44/35535\" title=\"figure 4\">",
"      Disease-specific survival MF SS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/34/11822\" title=\"table 1A\">",
"      Mycosis fungoides TNMB classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/56/15245\" title=\"table 1B\">",
"      Mycosis fungoides clinical staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/6/18541\" title=\"table 2\">",
"      Pretreatment evaluation MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/27/25021\" title=\"table 3\">",
"      mSWAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/17/39196\" title=\"table 4\">",
"      CAILS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/55/32638\" title=\"table 5\">",
"      Response criteria MF and SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4714="Management of celiac disease in adults";
var content_f4_38_4714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of celiac disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4714/contributors\">",
"     Paul J Ciclitira, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4714/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/38/4714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/38/4714/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/38/4714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease can be defined as a condition in which there is an abnormal small intestinal mucosa that improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced. The disorder is commonly referred to as \"celiac sprue\" or \"gluten-sensitive enteropathy\" in the United States. It was first described by Samuel Gee in 1887, although a similar description of a chronic malabsorptive disorder was recorded as far back as the second century AD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, there are six key elements in the management of patients with celiac disease, which can be summarized with the following acronym [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consultation with a skilled dietitian",
"     </li>",
"     <li>",
"      Education about the disease",
"     </li>",
"     <li>",
"      Lifelong adherence to a gluten-free diet",
"     </li>",
"     <li>",
"      Identification and treatment of nutritional deficiencies",
"     </li>",
"     <li>",
"      Access to an advocacy group",
"     </li>",
"     <li>",
"      Continuous long-term follow-up by a multidisciplinary team",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendations made in this topic are generally consistent with the guidelines on the recognition and assessment of celiac disease in children and adults from the British National Institute for Health and Clinical Excellence in 2009 and the American Gastroenterological Association (AGA) 2006 guidelines for the diagnosis and management of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/3\">",
"     3",
"    </a>",
"    ]. The discussion below also reflects a 2004 consensus statement issued by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of celiac disease and its complications will be reviewed here. Its pathogenesis, clinical manifestations, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIETARY COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of treatment of celiac disease is the elimination of gluten in the diet. Treatment of the patient with celiac disease begins with dietary counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7321257\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gluten-free diet is recommended in patients with celiac disease (classic disease, atypical celiac disease, and asymptomatic or silent celiac disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with latent celiac disease (positive IgA endomysial antibody, but normal small bowel biopsy) are currently not advised to be on a gluten-free diet but should continue to be monitored and rebiopsied if symptoms develop. However, it is important that histologically evident celiac disease was adequately evaluated in such patients with multiple intestinal biopsies since the histologic abnormalities can be patchy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of celiac disease\", section on 'Small bowel biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7321264\">",
"    <span class=\"h2\">",
"     Components of the gluten-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal sources of dietary gluten are wheat, rye, and barley. Consumption of a gluten-free diet requires a major lifestyle change since gluten is contained in a variety of foods that are commonly consumed in a Western diet. Thus, it is usually helpful to provide written information and dietary counseling to improve compliance. A number of resources are available for patients with celiac disease. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"     \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As general rules, the following dietary advice can be given to all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foods containing wheat, rye, and barley should be avoided.",
"     </li>",
"     <li>",
"      Soybean or tapioca flours, rice, corn, buckwheat, and potatoes are safe.",
"     </li>",
"     <li>",
"      Read labels on prepared foods and condiments carefully, paying particular attention to additives such as stabilizers or emulsifiers that may contain gluten.",
"     </li>",
"     <li>",
"      Distilled alcoholic beverages and vinegars, as well as wine, are gluten free. However, beers, ales, lagers, and malt vinegars should be avoided because they are often made from gluten-containing grains and are not distilled. However, in Europe gluten-free beers are now marketed and can be obtained worldwide.",
"     </li>",
"     <li>",
"      Dairy products may not be well tolerated initially since many patients with celiac disease can have secondary lactose intolerance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .) As a result, lactose-containing products should initially be avoided in patients whose symptoms appear to be worsened by them.",
"     </li>",
"     <li>",
"      Oat consumption should be limited to 50 to 60",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (approximately 2 oz) in patients with mild disease upon presentation or whose disease is in remission after a stringent gluten-free diet. The latter patients should be followed carefully for clinical or serologic evidence of disease recurrence after reintroducing oats. Patients with severe disease should avoid oats altogether.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although gluten is also found in oats, the toxicity of oats in celiac disease is now in doubt because some studies suggest that pure oat flour can be tolerated without disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/5-10\">",
"     5-10",
"    </a>",
"    ], while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, for example, 52 adults with celiac disease in remission and 40 with newly diagnosed celiac disease were randomly assigned to a gluten-free diet without oats, or a gluten-free diet with a total daily consumption of 50 to 70 g of oats [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/5\">",
"       5",
"      </a>",
"      ]. At the end of one year, no significant difference was observed in the nutritional status, symptoms, laboratory or histologic measures between the two groups. After 6 to 12 months of follow-up, the rate of disappearance of gliadin and reticulin antibodies and the decrease in intraepithelial lymphocytes were similar in the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/12\">",
"       12",
"      </a>",
"      ]. A follow-up report suggested that the ability to tolerate oats persisted for at least five years in the majority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somewhat different conclusions were reached in another controlled trial involving 39 adults who were randomly assigned to either a gluten-free diet with 50 g of oat-containing products daily or to a gluten-free diet without oats for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/11\">",
"       11",
"      </a>",
"      ]. Quality of life scores were similar between the groups, and there were no significant differences in the villous structure of small bowel biopsies. However, patients consuming oats had significantly more gastrointestinal symptoms (including diarrhea and constipation) and had a significantly higher density of intraepithelial lymphocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a few reasons why oats may be better tolerated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, even though oats contain a sequence homology (ie, QQQPF) with gliadin peptides, which have been shown to be disease activating, this homology may not be relevant since T-cell activation requires larger epitopes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Second, oats contain a relatively smaller proportion of this toxic prolamin moiety compared with other gluten-containing cereals. This hypothesis is supported by studies on oat challenge in patients with celiac disease, which suggest that tolerance to oats depends at least in part upon the total amount consumed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/15\">",
"       15",
"      </a>",
"      ]. Daily oats consumption less than 40 to 60",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      by patients whose celiac disease is in remission appears to be well tolerated, while larger daily intake is associated with disease recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/15\">",
"       15",
"      </a>",
"      ]. However, studies using these larger quantities were performed before the advent of small bowel biopsy.",
"     </li>",
"     <li>",
"      Finally, there may be variability in the immunogenicity of different oat cultivars, which may explain some of the disparate results when it comes to oat tolerability in patients with celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these observations, the long-term safety of oat consumption in patients with celiac disease is uncertain, and most studies that examined the safety of oats have included patients with relatively mild disease or whose disease was in remission upon reinstitution of oats in the diet. Furthermore, some patients may be exquisitely sensitive to oat prolamins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, at the present time, a reasonable approach is to limit oat consumption to 50 to 60",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (approximately 2 oz) in patients with mild disease upon presentation or whose disease is in remission after a stringent gluten-free diet. The latter patients should be followed carefully for clinical or serologic evidence of disease recurrence after reintroducing oats. Patients with severe disease should probably avoid oats altogether, especially since oat products obtained in the store are frequently contaminated with small amounts of other cereals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Is strict gluten avoidance necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As gluten elimination poses several lifestyle restrictions, compliance with a strict gluten-free diet is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/19\">",
"     19",
"    </a>",
"    ]. This is in part because the ability to tolerate gluten in the diet is highly variable among patients. While some patients are exquisitely sensitive to even small amounts of gluten, other patients can tolerate the reintroduction of small amounts in their diet after achieving remission.",
"   </p>",
"   <p>",
"    Despite this variable response, several arguments favor encouraging strict adherence to a gluten-free diet in most patients with established celiac disease regardless of clinical symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite feeling clinically well, patients may have a variety of micronutrient deficiencies that may ultimately have clinical sequelae such as bone loss due to vitamin D deficiency. These can be partially reversed with a gluten-free diet (see",
"      <a class=\"local\" href=\"#H1905366138\">",
"       'Prevention of bone loss'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple reports have suggested increased overall mortality and risk of malignancy (lymphoproliferative disease and gastrointestinal cancer) in patients with celiac disease compared to the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although, in one study, the increased risk of non-Hodgkin lymphoma persisted for five years after diagnosis despite adherence to a gluten-free diet [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/22\">",
"       22",
"      </a>",
"      ], several other studies have suggested that the risk is decreased in patients adhering to a gluten-free diet [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/23-26\">",
"       23-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least two studies found that the likelihood that patients with celiac disease will develop other autoimmune disorders associated with celiac disease (eg, type 1 diabetes mellitus, connective tissue diseases, Hashimoto's thyroiditis, and Graves' disease) appeared to be related to the duration of exposure to gluten [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/27,28\">",
"       27,28",
"      </a>",
"      ], although discordant data have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mothers with undiagnosed celiac disease appear to be at increased risk for having low birth weight newborns and preterm births compared to those whose disease has been diagnosed (and presumably treated) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trace amounts of gluten may be contained in products that are labeled as gluten-free. However, the small amount of gluten contained in these products does not necessarily cause treatment failure. A study evaluating occult gluten intake (from grain contaminants) among 76 patients on a gluten-free diet estimated that gluten contamination of up to 100 parts per million (up to a total of 30 mg per day) did not result in histologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/32\">",
"     32",
"    </a>",
"    ]. Interestingly, 13 of 59 naturally gluten-free products and 11 of 24 wheat starch-based gluten-free products contained gluten ranging from 20 to 200",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Medications (pills) generally contain minimal gluten and do not need to be avoided. Information about gluten-free drugs is available at",
"    <a class=\"external\" href=\"file://www.glutenfreedrugs.com/\">",
"     www.glutenfreedrugs.com",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING THE RESPONSE TO A GLUTEN-FREE DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapidity of the response to a gluten-free diet is variable. Approximately 70 percent of patients have noticeable clinical improvement within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/33\">",
"     33",
"    </a>",
"    ]. As a general rule, symptoms improve faster than histology, especially when biopsies are obtained in the proximal intestine. The reason is incompletely understood; however, a possible explanation is that the less severely damaged distal small intestine recovers faster than the proximal intestine, which is typically more severely affected due to relatively increased exposure to gluten [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with celiac disease should be monitored at regular intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. We suggest that patients be evaluated four to six weeks following the initiation of a gluten-free diet at which time a complete blood count, folate, B12, iron studies, liver chemistries, and serologic testing should be performed. It is important to note that women often experience breast tenderness for three months after starting a gluten-free diet and reassurance should be provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7321280\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IgA antigliadin antibody assay was previously the most frequently used test for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, with increased use of IgA tTG for initial diagnosis this assay is now also increasingly used in monitoring response to gluten-free diet.",
"   </p>",
"   <p>",
"    For whichever assay that will be used, a pretreatment antibody level should be determined at the time of diagnosis. Exclusion of gluten from the diet results in a gradual decline in serum IgA antigliadin and IgA tTG levels (half-life of six to eight weeks). A normal baseline value is typically reached within 3 to 12 months depending upon the pre-treatment concentrations. Normal IgA tTG levels do not reliably indicate recovery from villous atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/40\">",
"     40",
"    </a>",
"    ]. Conversely, if the levels do not fall as anticipated, the patient is usually continuing to ingest gluten either intentionally or inadvertently [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the general patterns above can be helpful, the accuracy of these tests in establishing compliance with a gluten-free diet is unsettled [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. The value of these tests in monitoring adherence to a gluten-free diet is particularly limited in three respects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The test is useless if antibody levels are not elevated prior to therapy.",
"     </li>",
"     <li>",
"      Interassay variations in test results may be substantial and make interpretation difficult. Serial samples should ideally be sent to one laboratory for testing to keep interassay variation to a minimum. Minor fluctuations in IgA antigliadin or IgA TTG levels are the norm and their importance should not be over interpreted.",
"     </li>",
"     <li>",
"      Persistently high antibody levels usually reflect continued exposure to substantial amounts of dietary gluten. However, antibody levels will fall when dietary gluten intake is reduced, and they are not a sensitive indicator of occasional or minor dietary transgressions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum IgG antigliadin and IgA endomysial antibody levels also fall when patients with celiac disease adhere to a strict gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/37,44,45\">",
"     37,44,45",
"    </a>",
"    ]. However, the decline in IgG antigliadin is more gradual than for IgA antigliadin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], making it less useful in monitoring recent dietary adherence. IgA endomysial antibody levels are more costly and results are more difficult to quantify than IgA antigliadin or IgA tTG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7322256\">",
"    <span class=\"h2\">",
"     Small bowel biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for a follow-up biopsy in patients with clinical improvement has been debated, especially since serologic testing can be used to monitor recovery and compliance with the diet. Some authorities rely on clinical improvement and changes in serologic markers, reserving re-biopsy for nonresponsive patients in whom there remains diagnostic uncertainty, or those who wish to confirm mucosal healing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The author's practice is to repeat a small intestinal biopsy in all patients three to four months after beginning a gluten-free diet to demonstrate histologic improvement. If improvement in small intestinal morphology is not seen, but symptomatic improvement has occurred, the diet should be continued and the small intestinal biopsy should be repeated after six to nine months. Although histological improvement is usually seen, persistent abnormalities have been described, even in patients with symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The significance is at the moment unclear, but this may be due to low level gluten contamination, a persistent immune response or other unknown mechanisms. Other diagnoses, after a first check for poor compliance, or inadvertent ingestion of gluten should be considered in these patients (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Other diagnoses'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7322438\">",
"    <span class=\"h2\">",
"     Gluten rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gluten rechallenge is unnecessary according to a consensus statement issued by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/2\">",
"     2",
"    </a>",
"    ]. Guidelines issued by the European Society of Paediatric Gastroenterology and Nutrition (ESPGAN) suggested that gluten rechallenge is not mandatory in patients with good improvement in symptoms, histology, and a decline in the titer of antiendomysial antibodies (which usually return to normal in three to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/48\">",
"     48",
"    </a>",
"    ]. According to the ESPGAN guidelines, gluten rechallenge should only be used in equivocal cases such as when no initial biopsy was performed, biopsies were inadequate or atypical, in communities with high rates of other enteropathies, or in situations when patients plan to abandon a gluten-free diet in an uncontrolled way. Gluten rechallenge should be performed after obtaining a control biopsy on a gluten-free diet and repeat biopsies should be obtained three to six months later with the recognition that relapse can take five to seven years or more.",
"   </p>",
"   <p>",
"    A rare hazard in giving a gluten rechallenge is the development of fulminant diarrhea, with resulting dehydration, acidosis, and other metabolic disturbances (a condition known as \"gliadin shock\") [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/49\">",
"     49",
"    </a>",
"    ]. Such patients should be treated with glucocorticoids. There is a suggestion that use of gluten challenge in young children may be associated with an increased likelihood of development of autoimmune disorders such as insulin dependent diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonresponders are individuals who have persistent symptoms or serologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic abnormalities after two years on a gluten-free diet. The majority of patients with celiac disease respond to a gluten-free diet but approximately 5 percent of individuals do not.",
"   </p>",
"   <p>",
"    In patients who are incomplete responders or nonresponders, it is important to consider that not all clinical features of celiac disease respond at the same rate (see",
"    <a class=\"local\" href=\"#H1905366228\">",
"     'Dermatitis herpetiformis'",
"    </a>",
"    below). Furthermore, bone loss due to secondary hyperparathyroidism and peripheral neuropathy may only improve partially despite a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not respond to a gluten-free diet fall into five main categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with poor compliance or inadvertent gluten ingestion",
"     </li>",
"     <li>",
"      Patients with clinical or histologic features that overlap with celiac disease but are caused by other disorders",
"     </li>",
"     <li>",
"      Patients with concurrent disorders",
"     </li>",
"     <li>",
"      Patients with refractory sprue",
"     </li>",
"     <li>",
"      Patients with ulcerative jejunitis or intestinal lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16578489\">",
"    <span class=\"h2\">",
"     Poor compliance or inadvertent gluten ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common reasons for a lack of response are poor compliance or inadvertent gluten ingestion (",
"    <a class=\"graphic graphic_table graphicRef79790 \" href=\"UTD.htm?32/1/32796\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In patients who continue to have symptoms or persistent histologic abnormalities, or in those in whom serum antibody titers have not declined, a meticulous dietary history should be obtained, and dietary counseling pursued with a dietitian specifically trained and experienced in celiac disease.",
"   </p>",
"   <p>",
"    One group proposed a short survey that on initial evaluation was a more accurate predictor of compliance with a gluten-free diet than serologic testing compared with a formal nutritional assessment as the reference standard [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/54\">",
"     54",
"    </a>",
"    ]. Additional validation studies are needed. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring the response to a gluten-free diet'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;An erroneous diagnosis of celiac sprue may result from false positive serology, specifically IgA antigliadin antibodies. Diseases associated with small bowel villous atrophy should be excluded in patients with persistent symptoms who do not show histologic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905367278\">",
"    <span class=\"h2\">",
"     Concurrent disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other concurrent diagnoses should be considered in patients who, despite apparent compliance, continue to have symptoms or do not have histologic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/51,56\">",
"     51,56",
"    </a>",
"    ]. In a series of 78 patients with celiac disease treated with a gluten-free diet for at least 12 months, persistent diarrhea was observed in 13 patients (17 percent) due to other concurrent diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concomitant or secondary lactose intolerance is a possible cause of continued diarrhea and flatulence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with celiac disease may have concurrent bowel disturbances such as irritable bowel syndrome, which affects a large proportion of the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"       \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small bowel bacterial overgrowth, which may respond to antibiotics, develops in a small percentage of patients with celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"       \"Treatment of small intestinal bacterial overgrowth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients have coexisting pancreatic insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"       \"Overview of the treatment of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microscopic colitis is found in 4 percent of patients with celiac disease, which represents a 70-fold increase in risk [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/60\">",
"       60",
"      </a>",
"      ]. These patients had more severe villous atrophy and frequently required glucocorticoids or immunosuppressive drugs to treat the diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=see_link\">",
"       \"Lymphocytic and collagenous colitis (microscopic colitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Refractory sprue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with refractory sprue (also referred to as \"unclassified sprue\") fall into two clinical categories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have no initial response to a gluten-free diet",
"     </li>",
"     <li>",
"      Patients who experience initial clinical improvement on a gluten-free diet, but, after a period of remission, develop disease refractory to gluten abstinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Refractory sprue has also been subdivided into two immunologic categories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 in which there is a normal population of intraepithelial lymphocytes.",
"     </li>",
"     <li>",
"      Type 2 in which there is an aberrant or premalignant population of intraepithelial lymphocytes based upon clonality analysis of T-cell receptors and immunophenotyping. Type 2 can progress to enteropathy-associated T-cell lymphoma, which may present clinically as ulcerative jejunitis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/64\">",
"       64",
"      </a>",
"      ]. The diagnosis can be established on biopsy; CT, MRI, and 18F-FDG PET scans can help identify suspicious areas [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ulcerative jejunitis and intestinal lymphoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with type 1 disease have a less severe presentation and a much better prognosis than patients with type 2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Furthermore, type 1 does not appear to evolve into type 2. An illustrative study compared outcomes in 41 patients with type 1 disease to 50 patients with type 2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/70\">",
"     70",
"    </a>",
"    ]. Five-year survival was higher in the type 1 group (96 versus 58 percent). Most deaths were due to development of T-cell lymphoma (which developed in one-half of patients during follow-up). No patient with type 1 disease developed type 2 disease during an average five years follow-up. A staging system (based upon age, hemoglobin, albumin, the presence of T-cell clones, and total villous atrophy) has been proposed and awaits further validation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Refractory sprue (particularly type 2) can be severe and associated with progressive malabsorption and death. A subset of patients develops subepithelial collagen deposition, a condition referred to as \"collagenous sprue\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of refractory sprue is unknown. It is possible that some patients with this condition develop sensitivity to a dietary constituent other than gluten [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/75\">",
"     75",
"    </a>",
"    ]. However, identification of the responsible antigens in most patients is difficult and unrewarding. As a result, treatment has focused on immunosuppression, which has traditionally relied upon glucocorticoids.",
"   </p>",
"   <p>",
"    The dose of glucocorticoids required varies among patients, and not all patients respond. In severely ill patients, we usually begin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (100 mg IV Q6H). Oral dosing (such as 40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    daily) can be used in patients who are tolerating an oral diet. After a few weeks, the dose can be reduced by 5 to 10 mg per day in responding patients and subsequently tapered to the lowest dose that keeps the patient in remission.",
"   </p>",
"   <p>",
"    Experience with alternative immunosuppressant therapy in patients who require high doses of glucocorticoids is limited to case reports and clinical experience. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercaptopurine, and thiopurine derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    (TG) appear to be effective steroid-sparing agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (9 mg, range 6 to 12 mg) has been effective in case series [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series described clinical and histologic improvement following treatment with an elemental diet in patients with type 1 refractory sprue [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small pilot study of 10 patients with type 1 refractory sprue treated with small intestinal release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      , 5 of 10 patients had a complete response and one had a partial response. Subgroup analysis showed that response did not significantly vary by concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      use [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report described remission in a patient with type 2 disease following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , an anti-CD52 monoclonal antibody used to treat chronic lymphocytic leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/83\">",
"       83",
"      </a>",
"      ]. However, the drug was not effective in other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      (a synthetic purine nucleoside with cytotoxic activity) was associated with clinical and histologic improvement in 6 of 17 patients with type 2 refractory sprue [",
"      <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ulcerative jejunitis and intestinal lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative jejunitis and lymphoma should be considered in patients with refractory sprue unresponsive to glucocorticoids. The conditions are thought to share a similar pathogenesis, since both have aberrant T-cell monoclonality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/24,86\">",
"     24,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ulcerative jejunitis have multiple chronic, benign-appearing ulcers, most frequently in the jejunum. Clinical manifestations are similar to severe celiac disease; patients may present with new or recurrent symptoms of malabsorption, lassitude, anorexia, weight loss, abdominal pain, diarrhea, and fever despite being on a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/87\">",
"     87",
"    </a>",
"    ]. Intestinal stricturing can develop with resulting small bowel obstruction. The disease most commonly presents in middle-aged patients with underlying celiac disease. Evaluation should begin with an abdominal computed tomography (CT) enterography or magnetic resonance (MR) enterography scan and upper endoscopy, which, if negative, should be followed by a capsule endoscopy. Ulcerative jejunitis responds poorly to a gluten-free diet and is associated with an unfavorable prognosis. Up to one-third of patients die from complications. The prognosis can be improved if the ulcerated or strictured segment can be resected.",
"   </p>",
"   <p>",
"    Lymphoma should be suspected in patients with celiac disease presenting with the clinical features described above for ulcerative jejunitis. Among patients who initially responded to a gluten-free diet, the diagnostic dilemma is whether the return of symptoms is due to dietary lapses or the development of lymphoma. Clinical manifestations more suggestive of lymphoma, such as fever, hepatomegaly, splenomegaly, duodenal mass(es), or ascites, may help the diagnostic conundrum, but their presence implies more advanced disease. Other presentations of lymphoma include acute perforation, gastrointestinal obstruction, or, less commonly, gastrointestinal hemorrhage.",
"   </p>",
"   <p>",
"    The evaluation should begin with an abdominal computed tomography (CT) enterography or magnetic resonance (MR) enterography scan, upper endoscopy and capsule endoscopy. In patients with lymphoma, the histology of adjacent intestine is often indistinguishable from untreated celiac disease. However, it remains uncertain whether these patients had occult celiac disease that became evident only after lymphoma developed, or whether the lymphoma caused the development of celiac-like histology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/88\">",
"     88",
"    </a>",
"    ]. A full-thickness surgical intestinal biopsy may be required to establish the diagnosis in patients in whom clinical suspicion is high, but radiographic and endoscopic testing is inconclusive. These lymphomas are almost always of high-grade histology and the prognosis is poor.",
"   </p>",
"   <p>",
"    Five-year survival is approximately 10 percent, with the worst outcomes in patients with previously diagnosed celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/89\">",
"     89",
"    </a>",
"    ]. Favorable outcomes with multidrug therapy occur only in patients who have minimal gastrointestinal symptoms prior to the diagnosis of lymphoma, and can tolerate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/89\">",
"     89",
"    </a>",
"    ]. Patients should also be maintained on a gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905366523\">",
"    <span class=\"h1\">",
"     OTHER ASPECTS OF MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905366097\">",
"    <span class=\"h2\">",
"     Repletion of nutritional deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific dietary deficiencies such as iron,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , calcium, vitamin D and, rarely, thiamine, vitamin B6 and B12 deficiency should be tested for and corrected. Mineral deficiencies including magnesium, zinc, copper and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    may also occur depending on the disease severity and dietary intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A gluten-free diet may induce troublesome constipation since it is low in roughage. This usually responds to fiber supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    seed husks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905366138\">",
"    <span class=\"h2\">",
"     Prevention of bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss (principally osteopenia and less often osteoporosis) is common in celiac disease, and can occur in patients without gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/20,90-92\">",
"     20,90-92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .) Much of the bone loss is related to secondary hyperparathyroidism, which is probably due to vitamin D deficiency. Patients with advanced disease may have bone pain, pseudofractures, or deformity, but the majority of patients are asymptomatic or have only raised serum levels of alkaline phosphatase or hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/20,93\">",
"     20,93",
"    </a>",
"    ]. It can only be partially reversed with a gluten-free diet; loss of bone density in the peripheral skeleton may persist despite apparent normalization at axial skeletal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients diagnosed with celiac disease should be evaluated for bone loss using a DEXA (dual energy x-ray absorptiometry) scan. Monitoring by repeat DEXA scan after one year is useful in patients with osteopenia since it permits estimation of the rate of change of bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/94\">",
"     94",
"    </a>",
"    ]. Treatment of osteoporosis and osteopenia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905366221\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated with hyposplenism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .) Therefore, prophylactic administration of pneumococcal vaccine is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1905366228\">",
"    <span class=\"h2\">",
"     Dermatitis herpetiformis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated with a number of skin disorders of which dermatitis herpetiformis is the most common (",
"    <a class=\"graphic graphic_table graphicRef71271 \" href=\"UTD.htm?3/19/3387\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link\">",
"     \"Dermatitis herpetiformis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in dermatitis herpetiformis following withdrawal of gluten may be considerably delayed (6 to 12 months) compared to the response of the intestinal manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/96\">",
"     96",
"    </a>",
"    ]. As a result, treatment with sulfones (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ) in addition to gluten avoidance may be necessary to achieve rapid control [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SCREENING FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatives of patients with celiac disease are at increased risk for having celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. The risk is highest among monozygotic twins (approximately 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/99\">",
"     99",
"    </a>",
"    ], HLA-identical siblings (approximately 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/99\">",
"     99",
"    </a>",
"    ], and among first-degree relatives of families with at least two affected siblings (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/97\">",
"     97",
"    </a>",
"    ]. Among first-degree relatives, the risk has varied from 5 to 11 percent in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In one report, the risk was highest among male siblings, almost one-half of whom had clinically silent celiac disease despite severe intestinal villous atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/38/4714/abstract/100\">",
"     100",
"    </a>",
"    ]. Thus, screening of first-degree relatives (particularly siblings) should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of celiac disease\", section on 'Individuals with a moderate or high risk for celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=see_link\">",
"       \"Patient information: Celiac disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/9/25746?source=see_link\">",
"       \"Patient information: Gluten-free diet (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"       \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac disease can be defined as a condition in which there is an abnormal small intestinal mucosa that improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced.",
"     </li>",
"     <li>",
"      We recommend that patients with serologically and histologically confirmed celiac disease and compatible clinical or laboratory manifestations adhere to a gluten-free diet (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7321257\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with celiac disease be referred to a dietitian who is familiar with counseling patients on a gluten-free diet. Providing written information and referral to a support group can also be helpful. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"       \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific dietary deficiencies such as iron,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , calcium, vitamin D, and, rarely, thiamine, vitamin B6 and B12 deficiency should be corrected. A gluten-free diet may induce troublesome constipation since it is low in roughage. This usually responds to the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      seed husks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"       \"Overview of the treatment of malabsorption\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1905366097\">",
"       'Repletion of nutritional deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone loss (principally osteopenia and less often osteoporosis) is common in celiac disease, and can occur in patients without gastrointestinal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Much of the bone loss is related to secondary hyperparathyroidism, which is probably due to vitamin D deficiency. It can only be partially reversed with a gluten-free diet. Patients diagnosed with celiac disease should be evaluated for bone loss using a DEXA (dual energy x-ray absorptiometry) scan and appropriate therapy instituted based upon the results. (See",
"      <a class=\"local\" href=\"#H1905366138\">",
"       'Prevention of bone loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal vaccination is suggested since celiac disease is associated with hyposplenism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should be followed clinically and with serologic testing to determine response to dietary therapy. The need for a follow-up biopsy in patients with clinical improvement has been debated. However, the author's practice is that a repeat small intestinal biopsy be obtained three to four months after beginning a gluten-free diet to demonstrate histologic improvement. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring the response to a gluten-free diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with celiac disease respond to a gluten-free diet. The most common reasons for a lack of response are poor compliance or inadvertent gluten ingestion (",
"      <a class=\"graphic graphic_table graphicRef79790 \" href=\"UTD.htm?32/1/32796\">",
"       table 1",
"      </a>",
"      ). Thus, we suggest a meticulous dietary history should be obtained, and dietary counseling pursued with an experienced dietitian in patients who continue to have symptoms or persistent histologic abnormalities, or in those in whom serum antibody titers have not declined. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonresponders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not respond despite adherence to a gluten-free diet fall into four main categories, those with: clinical or histologic features that are caused by other disorders; concurrent conditions, refractory sprue; ulcerative jejunitis or intestinal lymphoma. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonresponders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Adams F. The extant works of Aretaeus the Cappadocian, London Sydenham Society, 1856.",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: file://consensus.nih.gov/ (Accessed on March 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/3\">",
"      AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/4\">",
"      Ravelli A, Bolognini S, Gambarotti M, Villanacci V. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. Am J Gastroenterol 2005; 100:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/5\">",
"      Janatuinen EK, Pikkarainen PH, Kemppainen TA, et al. A comparison of diets with and without oats in adults with celiac disease. N Engl J Med 1995; 333:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/6\">",
"      Srinivasan U, Leonard N, Jones E, et al. Absence of oats toxicity in adult coeliac disease. BMJ 1996; 313:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/7\">",
"      Hardman CM, Garioch JJ, Leonard JN, et al. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1997; 337:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/8\">",
"      Janatuinen EK, Kemppainen TA, Julkunen RJ, et al. No harm from five year ingestion of oats in coeliac disease. Gut 2002; 50:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/9\">",
"      H&ouml;gberg L, Laurin P, F&auml;lth-Magnusson K, et al. Oats to children with newly diagnosed coeliac disease: a randomised double blind study. Gut 2004; 53:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/10\">",
"      Cooper SE, Kennedy NP, Mohamed BM, et al. Immunological indicators of coeliac disease activity are not altered by long-term oats challenge. Clin Exp Immunol 2013; 171:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/11\">",
"      Per&auml;aho M, Kaukinen K, Mustalahti K, et al. Effect of an oats-containing gluten-free diet on symptoms and quality of life in coeliac disease. A randomized study. Scand J Gastroenterol 2004; 39:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/12\">",
"      Janatuinen EK, Kemppainen TA, Pikkarainen PH, et al. Lack of cellular and humoral immunological responses to oats in adults with coeliac disease. Gut 2000; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/13\">",
"      Sturgess R, Day P, Ellis HJ, et al. Wheat peptide challenge in coeliac disease. Lancet 1994; 343:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/14\">",
"      Shidrawi RG, Day P, Przemioslo R, et al. In vitro toxicity of gluten peptides in coeliac disease assessed by organ culture. Scand J Gastroenterol 1995; 30:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/15\">",
"      Schmitz J. Lack of oats toxicity in coeliac disease. BMJ 1997; 314:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/16\">",
"      Comino I, Real A, de Lorenzo L, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease. Gut 2011; 60:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/17\">",
"      Lundin KE, Nilsen EM, Scott HG, et al. Oats induced villous atrophy in coeliac disease. Gut 2003; 52:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/18\">",
"      Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med 2004; 351:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/19\">",
"      Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/20\">",
"      Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/21\">",
"      West J, Logan RF, Smith CJ, et al. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004; 329:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/22\">",
"      Green PH, Fleischauer AT, Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/23\">",
"      Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease--effect of a gluten free diet. Gut 1989; 30:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/24\">",
"      Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001; 358:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/25\">",
"      Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/26\">",
"      Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/27\">",
"      Ventura A, Magazz&ugrave; G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/28\">",
"      Cosnes J, Cellier C, Viola S, et al. Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 2008; 6:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/29\">",
"      Sategna Guidetti C, Solerio E, Scaglione N, et al. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 2001; 49:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/30\">",
"      N&oslash;rg&aring;rd B, Fonager K, S&oslash;rensen HT, Olsen J. Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/31\">",
"      Ludvigsson JF, Montgomery SM, Ekbom A. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology 2005; 129:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/32\">",
"      Collin P, Thorell L, Kaukinen K, M&auml;ki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004; 19:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/33\">",
"      Pink IJ, Creamer B. Response to a gluten-free diet of patients with the coeliac syndrome. Lancet 1967; 1:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/34\">",
"      MACDONALD WC, BRANDBORG LL, FLICK AL, et al. STUDIES OF CELIAC SPRUE. IV. THE RESPONSE OF THE WHOLE LENGTH OF THE SMALL BOWEL TO A GLUTEN-FREE DIET. Gastroenterology 1964; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/35\">",
"      Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/36\">",
"      Herman ML, Rubio-Tapia A, Lahr BD, et al. Patients with celiac disease are not followed up adequately. Clin Gastroenterol Hepatol 2012; 10:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/37\">",
"      B&uuml;rgin-Wolff A, Gaze H, Hadziselimovic F, et al. Antigliadin and antiendomysium antibody determination for coeliac disease. Arch Dis Child 1991; 66:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/38\">",
"      Kelly CP, Feighery CF, Gallagher RB, et al. Mucosal and systemic IgA anti-gliadin antibody in celiac disease. Contrasting patterns of response in serum, saliva, and intestinal secretions. Dig Dis Sci 1991; 36:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/39\">",
"      Kilander AF, Nilsson LA, Gillberg R. Serum antibodies to gliadin in coeliac disease after gluten withdrawal. Scand J Gastroenterol 1987; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/40\">",
"      Hopper AD, Hadjivassiliou M, Hurlstone DP, et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008; 6:314.",
"     </a>",
"    </li>",
"    <li>",
"     Kelly CP. Coeliac disease: Non-invasive tests to screen for gluten sensitive enteropathy and to monitor response to dietary therapy, Dublin University, Trinity College, Dublin 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/42\">",
"      Leffler DA, Edwards George JB, Dennis M, et al. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther 2007; 26:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/43\">",
"      Vahedi K, Mascart F, Mary JY, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003; 98:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/44\">",
"      Kapuscinska A, Zalewski T, Chorzelski TP, et al. Disease specificity and dynamics of changes in IgA class anti-endomysial antibodies in celiac disease. J Pediatr Gastroenterol Nutr 1987; 6:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/45\">",
"      Kumar V, Lerner A, Valeski JE, et al. Endomysial antibodies in the diagnosis of celiac disease and the effect of gluten on antibody titers. Immunol Invest 1989; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/46\">",
"      Lee SK, Lo W, Memeo L, et al. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/47\">",
"      Selby WS, Painter D, Collins A, et al. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/48\">",
"      Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990; 65:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/49\">",
"      KRAINICK HG, DEBATIN F, GAUTIER E, et al. [Additional research on the injurious effect of wheat flour in celiac disease.I. Acute gliadin reaction (gliadin shock)]. Helv Paediatr Acta 1958; 13:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/50\">",
"      Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/51\">",
"      Abdulkarim AS, Burgart LJ, See J, Murray JA. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002; 97:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/52\">",
"      Leffler DA, Dennis M, Hyett B, et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007; 5:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/53\">",
"      Dewar DH, Donnelly SC, McLaughlin SD, et al. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol 2012; 18:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/54\">",
"      Leffler DA, Dennis M, Edwards George JB, et al. A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol 2009; 7:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/55\">",
"      Shah VH, Rotterdam H, Kotler DP, et al. All that scallops is not celiac disease. Gastrointest Endosc 2000; 51:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/56\">",
"      Fine KD, Meyer RL, Lee EL. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology 1997; 112:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/57\">",
"      Rubio-Tapia A, Barton SH, Rosenblatt JE, Murray JA. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol 2009; 43:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/58\">",
"      Tursi A, Brandimarte G, Giorgetti G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 2003; 98:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/59\">",
"      Carroccio A, Iacono G, Lerro P, et al. Role of pancreatic impairment in growth recovery during gluten-free diet in childhood celiac disease. Gastroenterology 1997; 112:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/60\">",
"      Green PH, Yang J, Cheng J, et al. An association between microscopic colitis and celiac disease. Clin Gastroenterol Hepatol 2009; 7:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/61\">",
"      Trier JS, Falchuk ZM, Carey MC, Schreiber DS. Celiac sprue and refractory sprue. Gastroenterology 1978; 75:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/62\">",
"      Ryan BM, Kelleher D. Refractory celiac disease. Gastroenterology 2000; 119:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/63\">",
"      Mulder CJ, Wahab PJ, Moshaver B, Meijer JW. Refractory coeliac disease: a window between coeliac disease and enteropathy associated T cell lymphoma. Scand J Gastroenterol Suppl 2000; :32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/64\">",
"      Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/65\">",
"      Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/66\">",
"      Bagdi E, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999; 94:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/67\">",
"      Olaussen RW, L&oslash;vik A, Tollefsen S, et al. Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. Clin Gastroenterol Hepatol 2005; 3:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/68\">",
"      Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006; 47:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/69\">",
"      Van Weyenberg SJ, Meijerink MR, Jacobs MA, et al. MR enteroclysis in refractory celiac disease: proposal and validation of a severity scoring system. Radiology 2011; 259:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/70\">",
"      Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007; 56:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/71\">",
"      Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009; 136:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/72\">",
"      Gao Y, Kristinsson SY, Goldin LR, et al. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 2009; 136:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/73\">",
"      Rubio-Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/74\">",
"      McCashland TM, Donovan JP, Strobach RS, et al. Collagenous enterocolitis: a manifestation of gluten-sensitive enteropathy. J Clin Gastroenterol 1992; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/75\">",
"      Baker AL, Rosenberg IH. Refractory sprue: recovery after removal of nongluten dietary proteins. Ann Intern Med 1978; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/76\">",
"      Rolny P, Sigurjonsdottir HA, Remotti H, et al. Role of immunosuppressive therapy in refractory sprue-like disease. Am J Gastroenterol 1999; 94:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/77\">",
"      Vaidya A, Bolanos J, Berkelhammer C. Azathioprine in refractory sprue. Am J Gastroenterol 1999; 94:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/78\">",
"      Mauri&ntilde;o E, Niveloni S, Cher&ntilde;avsky A, et al. Azathioprine in refractory sprue: results from a prospective, open-label study. Am J Gastroenterol 2002; 97:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/79\">",
"      Tack GJ, van Asseldonk DP, van Wanrooij RL, et al. Tioguanine in the treatment of refractory coeliac disease--a single centre experience. Aliment Pharmacol Ther 2012; 36:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/80\">",
"      Daum S, Ipczynski R, Heine B, et al. Therapy with budesonide in patients with refractory sprue. Digestion 2006; 73:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/81\">",
"      Brar P, Lee S, Lewis S, et al. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007; 102:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/82\">",
"      Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/83\">",
"      Vivas S, Ruiz de Morales JM, Ramos F, Su&aacute;rez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006; 354:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/84\">",
"      Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med 2006; 355:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/85\">",
"      Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006; 4:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/86\">",
"      Ashton-Key M, Diss TC, Pan L, et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997; 151:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/87\">",
"      Bayless TM, Kapelowitz RF, Shelley WM, et al. Intestinal ulceration--a complication of celiac disease. N Engl J Med 1967; 276:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/88\">",
"      Isaacson PG. Intestinal lymphoma and enteropathy. J Pathol 1995; 177:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/89\">",
"      Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995; 21:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/90\">",
"      Walters JR, Banks LM, Butcher GP, Fowler CR. Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995; 37:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/91\">",
"      Mustalahti K, Collin P, Siev&auml;nen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/92\">",
"      Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol 2001; 96:112.",
"     </a>",
"    </li>",
"    <li>",
"     Cooke WT, Holmes GK. Clinical presentation. In: Coeliac Disease, Cooke WT, Holmes GK (Eds), Churchill Livingston, London 1984. p.90.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/94\">",
"      Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/95\">",
"      Fry L. Dermatitis herpetiformis. Baillieres Clin Gastroenterol 1995; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/96\">",
"      Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/97\">",
"      Book L, Zone JJ, Neuhausen SL. Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol 2003; 98:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/98\">",
"      Gudj&oacute;nsd&oacute;ttir AH, Nilsson S, Ek J, et al. The risk of celiac disease in 107 families with at least two affected siblings. J Pediatr Gastroenterol Nutr 2004; 38:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/99\">",
"      Greco L, Romino R, Coto I, et al. The first large population based twin study of coeliac disease. Gut 2002; 50:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/100\">",
"      Rubio-Tapia A, Van Dyke CT, Lahr BD, et al. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol 2008; 6:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/38/4714/abstract/101\">",
"      Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163:286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4777 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4714=[""].join("\n");
var outline_f4_38_4714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIETARY COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7321257\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7321264\">",
"      Components of the gluten-free diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Is strict gluten avoidance necessary?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING THE RESPONSE TO A GLUTEN-FREE DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7321280\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7322256\">",
"      Small bowel biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7322438\">",
"      Gluten rechallenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16578489\">",
"      Poor compliance or inadvertent gluten ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1905367278\">",
"      Concurrent disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Refractory sprue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ulcerative jejunitis and intestinal lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1905366523\">",
"      OTHER ASPECTS OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1905366097\">",
"      Repletion of nutritional deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1905366138\">",
"      Prevention of bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1905366221\">",
"      Pneumococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1905366228\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SCREENING FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4777|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/1/32796\" title=\"table 1\">",
"      Foods products with gluten",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/19/3387\" title=\"table 2\">",
"      Skin disorders associated with celiac disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=related_link\">",
"      Lymphocytic and collagenous colitis (microscopic colitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=related_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/9/25746?source=related_link\">",
"      Patient information: Gluten-free diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_38_4715="Cancer related fatigue initial workup";
var content_f4_38_4715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cancer-related fatigue: Initial diagnostic work-up",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolytes (sodium, potassium, chloride, bicarbonate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemistry panel (creatinine, blood urea nitrogen, glucose, magnesium, calcium, phosphorus, total bilirubin, serum transaminases, alkaline phosphatase, lactic dehydrogenase, albumin, total protein)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid stimulating hormone (TSH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count (CBC) with differential and platelet count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Serum testosterone, in men if&nbsp;the clinical history suggestive of hypogonadism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Escalante CP, Manzullo MD, Valdrez R. A cancer-related fatigue clinic: Opportunities and challenges.&nbsp;J Nat Canc Inst&nbsp;2003; 1:333. Copyright &copy;2003 Jones and Bartlett Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4715=[""].join("\n");
var outline_f4_38_4715=null;
var title_f4_38_4716="VNS settings";
var content_f4_38_4716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vagus nerve stimulator: adjustable parameters and initial settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial settings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adjusted settings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        On time",
"       </td>",
"       <td>",
"        30 seconds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Off time",
"       </td>",
"       <td>",
"        5 minutes",
"       </td>",
"       <td>",
"        5, 3, 1.8, 1.1 minutes",
"       </td>",
"       <td>",
"        Decreasing off time, (increasing the duty cycle) may improve efficacy, but may decrease tolerability and battery life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Output current",
"       </td>",
"       <td>",
"        0.25 mA",
"       </td>",
"       <td>",
"        0.25 mA to 3.5 mA",
"       </td>",
"       <td>",
"        Increased current may improve efficacy, but may decrease tolerability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        30 Hz",
"       </td>",
"       <td>",
"        20 to 30 Hz",
"       </td>",
"       <td>",
"        Decreasing frequency may improve tolerability without affecting efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulse width",
"       </td>",
"       <td>",
"        500 useconds",
"       </td>",
"       <td>",
"        250, 500 useconds",
"       </td>",
"       <td>",
"        Decreasing frequency may improve tolerability without affecting efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnet current",
"       </td>",
"       <td>",
"        0.5 mA",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnet duration",
"       </td>",
"       <td>",
"        60 seconds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnet pulse width",
"       </td>",
"       <td>",
"        500 useconds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4716=[""].join("\n");
var outline_f4_38_4716=null;
var title_f4_38_4717="Injury prevention resources US";
var content_f4_38_4717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Injury prevention resources (US)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advocates for Highway and Auto Safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-408-1711",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.saferoads.org\" target=\"_blank\">",
"         www.saferoads.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Centers for Disease",
"        <span class=\"subtitle2_single\">",
"         Control",
"        </span>",
"        and Prevention Protect the Ones You Love",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cdc.gov/safechild\" target=\"_blank\">",
"         www.cdc.gov/safechild",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Child Welfare League of America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-688-4200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cwla.org\" target=\"_blank\">",
"         www.cwla.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children's Safety Network",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.childrenssafetynetwork.org\" target=\"_blank\">",
"         www.childrenssafetynetwork.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Harborview Injury Prevention and Research Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.depts.washington.edu/hiprc\" target=\"_blank\">",
"         www.depts.washington.edu/hiprc",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Control and Emergency Health Services Section of the American Public Health Association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.apha.org/membergroups/sections/aphasections/icehs\" target=\"_blank\">",
"         www.apha.org/membergroups/sections/aphasections/icehs",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Prevention Research Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.public-health.uiowa.edu/IPRC\" target=\"_blank\">",
"         www.public-health.uiowa.edu/IPRC",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mothers Against Drunk Driving-MADD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        877-275-6233, 877-ASK-MADD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.madd.org\" target=\"_blank\">",
"         www.madd.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Safe Kids Campaign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-662-0600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.safekids.org\" target=\"_blank\">",
"         www.safekids.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Safety Council",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-621-7615",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.nsc.org\" target=\"_blank\">",
"         www.nsc.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Center for Injury Prevention and Control (NCIPC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-232-4636",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cdc.gov/injury/index.html\" target=\"_blank\">",
"         www.cdc.gov/injury/index.html",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        US Consumer Product Safety Commission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-638-2772 (hotline), 800-638-CPSC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cpsc.gov\" target=\"_blank\">",
"         www.cpsc.gov",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mace SE, Gerardi MJ, Dietrich AM, et al. Ann Emerg Med 2001; 38:405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4717=[""].join("\n");
var outline_f4_38_4717=null;
var title_f4_38_4718="TNM staging system vulvar melanoma";
var content_f4_38_4718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2002 AJCC TNM staging system for vulvar melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"4\">",
"            Clinical stage grouping",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage 0",
"           </td>",
"           <td>",
"            Tis",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage 1A",
"           </td>",
"           <td>",
"            T1a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IB",
"           </td>",
"           <td>",
"            T1b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T2a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IIA",
"           </td>",
"           <td>",
"            T2b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T3a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IIB",
"           </td>",
"           <td>",
"            T3b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T4a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage IIC",
"           </td>",
"           <td>",
"            T4b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"3\">",
"            Stage III",
"           </td>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            N1",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            N2",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            N3",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage IV",
"           </td>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            Any N",
"           </td>",
"           <td>",
"            M1",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"4\">",
"            Pathologic stage grouping",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage 0",
"           </td>",
"           <td>",
"            Tis",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage IA",
"           </td>",
"           <td>",
"            T1a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IB",
"           </td>",
"           <td>",
"            T1b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T2a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IIA",
"           </td>",
"           <td>",
"            T2b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T3a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage IIB",
"           </td>",
"           <td>",
"            T3b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T4a",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage IIC",
"           </td>",
"           <td>",
"            T4b",
"           </td>",
"           <td>",
"            N0",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"2\">",
"            Stage II1A",
"           </td>",
"           <td>",
"            T1-4a",
"           </td>",
"           <td>",
"            N1a",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4a",
"           </td>",
"           <td>",
"            N2a",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"5\">",
"            Stage IIIB",
"           </td>",
"           <td>",
"            T1-4b",
"           </td>",
"           <td>",
"            N1a",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4b",
"           </td>",
"           <td>",
"            N2a",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4a",
"           </td>",
"           <td>",
"            N1b",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4a",
"           </td>",
"           <td>",
"            N2b",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4a/b",
"           </td>",
"           <td>",
"            N2c",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td rowspan=\"3\">",
"            Stage II1C",
"           </td>",
"           <td>",
"            T1-4b",
"           </td>",
"           <td>",
"            N1b",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            T1-4b",
"           </td>",
"           <td>",
"            N2b",
"           </td>",
"           <td>",
"            M0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            N3",
"           </td>",
"           <td>",
"            M1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stage IV",
"           </td>",
"           <td>",
"            Any T",
"           </td>",
"           <td>",
"            Any N",
"           </td>",
"           <td>",
"            M1",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4718=[""].join("\n");
var outline_f4_38_4718=null;
var title_f4_38_4719="Atrophie blanche";
var content_f4_38_4719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophie blanche",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEANIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxLHNO4xgcsT17U2hRk8dTWJ2jwo3AA5/DvU6rkA5K49//AK1RqgKnuOgPQVbiBxluvtwPyoYMjdQ52tjj2xz601cb87GDY6e2OtWAMZxTWUdAMnqM+tIVxRkdSeaUgHPoabnqCR6nnoKfSEJjmlA4pOhz2p688UAJXb+DIitkH4LM35f/AFulcWo45HGK9G8KW/k2VsANoKA4GOc81nV+E1pLU7K0yMDgjvkd62LZv7y5OOCBWTZAtwTnHQVqR5CjAz9OK5obnRUXQtwElR0J9cdKeVJbKnB6896dCMqD698089ev1q5a7mSdnoUp0ZyABz14HWpIAY0IcYA7k9qsqvO7OKYyJ5isQCeQM+lZqDWpo6l1yiBg6EKTgjiqdy212DDj1z3q78pY7MsAMY96qOhZC5yOTznqKmRUUiFe4JPA3e3Sq87DeclsdhU7OFcbDuYcZNVH+vFZzZtTRmXTbmbCnj8KybiTJ749MY6VrXgAEa8qcYGe4FYd5mLIU8Zpxdy5RSdyjO+WyOOMYrLvMSwuB9/BAz2OTVuckyYyDjq2c/lVeRmMpAwAeWP/ANetYuwuW5zBkkBwSMjrgUVoy2OZHIYYJPYf4UVvdGZxgBJ5zknqaVRtbIJ47inKckjGc8cfzFD4425bsOOPrXScBLEVAyxAB9B1/wA5qwFxjHHsKrwEj5VGT1IbirIx9KTJYtB/SjNAPSkIQKATgYzS0uM9KBjHA5oAX6nvSjuCef0pBjI9P1o4PXmgaJY/mb1OQOa9S0RAlvCF4wAePpXmFoC1zCuOrgfhmvVrCMRxLg8AYFYV3ZG9Fam5YANyMAEcZ/pWpbEbucnP4Vm2LcAdRjgEda07fIUtyMc5/pXKpWOqcb6MvxNkZxkdMelOBzwOo9+1QoytHkfUjGKkBGScHg0cxnykiMWyMcgUhU7QG6nr9KVWG4DJyRwKU5C4K7gOnrVrVakPR6DCoAZc89MVXkQjq27tg+9WgwPKsDk9j1FQPycgZx1qJJWLje+pRugqvtXaGXqR0+lUnIRGbHTnmr1ztKsScPn7uelZ077F3bjgnAwOaxerOqCsineiTZzgheB7nHWsHUwPL+6cnB3A5rakkLthuo568Vj3koKnGTtyd/tVU99S6i00MOeRUBJIz0xmqxPlOX2n5hjOc9Kdevjk98DBFUXuQHDbhkKcHrz6VulcmK0GySymRsK2MnHyn/Cis976UuxwevZ8UVtyk2fY5lTnjPFOwWJORkmo+2aePXiuo8smj2jeTl/fHGP8asRnqvp71SXlsc89vWrgycknB/I4pMTJKO3vQM0Z6UiRTQDx9aSigBR704de+aTHBzTwOcDr70DRf0OHzNSgXg4O45r1GxUBQQeOlef+EYN9+X5OBj8a9ItFHlDd3rlr72OqitLlu2yGDY3H7vStaJsRkAgHrmsi3JZkG4Yz2H6VpRPgEN35/GuZnU0aEbLjPapGbyyFB/Kqccp81Sq4XOM4p5cxyspwy4/L61NyXAuRjjOQSelPZlOCwOQec/xCooT0AIbaOeeppJZW3NGhy3UZq7pIy5W2OwqbsLtU8D6/4VAZsK28fOD82DwfpTJH3Qhmkx/ewv0qnI/l4AywI6dahy7G0YXWo+5kEx6DA/X3qnKyqGJzyMZHFSO+1Qcjd2B9KzZsMxJyWxn0rNu7OiEOnQpy5w2QNrehrKu2CR7RgEjgetXpmIJDt8rH72Kxb1y0hVT83v8A0rWO4nrdNmTeu2SDgnOR9axbnco8pm2q2cEjOOK17/5TyMkYwSBxxWDeu5YkNjGdwPoa6YjjsZhubkHCxjaOmaKebmdSV81uOOgorYnl8iiF3YC459fpTlBXOcD3x0pwUByDzj0HarG3PA5PQn0rY8i5GqkFsEjPcDr6VMAc98e9KvAx/kUuB2pE3DoM0ZHtRUYUYJBznueaBD1GOAcinGkGRjNOH0oAB604HB/Sme1KOSAM5JwPrQUjtvBkG22aUjluQfb/ADiu4jG2NBtGenFYPh62ENnEmBkAYz3reYhMdQOtcVR3dztoroWrYYc4zweB2q5uKsQpxn3qCz5UsRgk81I+ASeMDjPeuebOiKuyeLLRnaT/ALvrThKBLsOWG7OarxTnOB8oPc8Ux3UAgD6VnzGvI3ozRWbMigEYwXJzjGB0pZbjCb2OCQQrDHB75qioOUdCGZuTj0NT7hGR5jBsZJGc/rTUmS6aWxYE3mW4wDkgFD3PHFUbicyAYUA9yB39Knc+TCRu5/hPUEd/8+9Qv+7RVyM4OR2Jpt30JiklcrTsfLJBGB1zVG6mXnGSuMVLcXB8s7E4x90gc1l3EjMwLgDHIUcUkjeOi1KdwSHYnOwdAByeKyrhgHYIpD+uc1qXoZoyAcAdR61hSy8kNg5OAc1tBES11Kt5GcFmOf4sDt2xWRcr8wXGOOQK32CsGLrngqfT2rKuIhFgbeh5wOOa3TuSnY554W3H58c+tFbBCgkYairuXzeRz6nJYDO4de3FT85PTgetVYyf4XPHFTrgFemfQdcmug8RkgPPXmlppOBzx70gfOPfpQSPPNLzkd6bkAZPApw60AKBmjr0x/jSe1KCMHjmgaE78Vb0mLztRgXoN249+BVar+hg/b1YDgDk+lTLY0pxvJI9L0ghlXbgZOev+eKh1u8aG8hiH3mYBgKl0gAKNo6gHPfNWZtPF1qMEzqCYznA61wydz0KSUWbdn80a/rinSE/Ng9eB7U2J1jJU8YHLE9DUck0IIO/gHt71hPXY1gncgMh2kH723OM+nekjMhyNysMZyRz1/8A10rk5kYAEY6561HauApkYEAt36VmkdS1WhohgzqAn0PrU22IK/ykjqu09DVRPM+1hLeNZcoCSMfLznt9KuxKz/vJGBAJCBTkN6jP/wBb1q1F72MZ2XUYyhiSzMXGc5OPyqOZf3R3sxUpwMVYDKYmwwJJ4JxjH+cVG0YLDJ5VcgDtRZ9CW+5kGOM7RCpxnlwO3pVG8whA4J5GTV+SQITnO1TkknGT+FZN2fMbK9MevX60Lc2UboqXbl+APlBzkGsJ9zTAnlQTyBgmta5cxxEqSDnv2rPkYEs4IJ6jPSt4Gck0ivI21VCnoeBVS6VjEvy7sMAVx2qwozuPG3HB/XpQm4LtI25Gdw5wPf2rVOxm9jKw4+6z47c0Va8t+wlHsHHFFaGXMcgi4bnOOM57VKTtU7R3/vVErEyYPyse5HSnKWPB3ZHXn29a6DzR7uQBnOM8Y65pRgHPOfXtUfTlR159j7fzpykhsbeg6A0CJEJ4yAB0qQdKiRQFGBg+/PNPyMGgQ7PNKO9NXnGDkU4UALnPOKu2cRbyBlwshOCnXdnjPtgGqWK63QbJmitWwBx+ZNZzdkdGH+K7Ox8OwH7OgI+fHBroY0XaXx25zVLT4VihRDggjFXpcm2KqAcjgDtXFPY6o+87mBcX229I5ZT8ucZzVwAsq7j8gJ6fSspraQX7ruxzk8VqzKFBVRwuOen1rLoelKyaSKWoyGziknV8DcFGTyfWqlxeNHNKA0oYphfl5cnPftyKpeJrj5UjORgknb97PFRaIjT3G6fdEFky+R36AY9c+tOMVy3OyFO0bs9B8OSrHZRQMUN3ekRsCv3FAyR2Ofc9Mmppf3dra29uD5cZzk9OT2/z0qlpt/tklMTmN9oUOMHnODjjv/npVyGLYx2A7uGYM2cH1H4AVvKacFFHjzi41HJ+v9fLQRlVSQoPbKkD+f5VFO8fl5P8P3s8irl2qKTtb3O4/dHf6msrBQyYJ2tyVbt1rmn7uhUPfVzN1BjIBkkAdBn3rPcgKUBAA5OfWrV2+ZdrM23HH0/z2qlOFRMZGSPypm6dtDPulDxLlckHPNZxVlJ65XtjFaM06gFcgEZ49aoyA/MW9+p960iDV0Q7cgA5APGT1P4VVZmW5ZVXC5x179On0q6hIbOM+mabc4jVZcHfj5QO5rQwKYIxyV/Eiil8tG5x15oqyOZHDoPmA6E+1SRgZIbgg5pCgIbngHr3/GlZgrBVOCc7c9T9K6zyiRwWwBnkdD60i5GFGcfWhO/TPc/571IASvrn3oEIik8t1PBpwUAcClwfwoU59j3pCHKPQ5p6jPSmipFY5B4pjQhUkkdzXpnhy0AigyBwP5elcBpcBudTt4gBywJJ9BzXqulosa47gAZ71hWeyN6KNe2+9jPIH6VZIBjxxjHaq9uDuOW7ZORVztxjk1zS1OmOjMk2S7mkBy3Uc9vSmyAR7c5U+1aMjhF3FfxPH4VXkAaRX7g9fWsXZaHXGberOF8T/vrqNHUIvJLYAHHp71W06by0ZXIaOQjdtbJ9l+vNdHq+kpdzSuwG3OOaNG0FYp380/Ki/KrdAauM0lZnq+1jyXuaumpcWunxCQZO4sqdCj9PxGCa2oGfYwfHzLkbfTPXn3/pVRVLeYTkYbvzjjrmrax7kMgOM+v06fhSTbPLqtPViyMskW13Zm7lu4+vrxVG8SMo/Xd7sRnHcVZnkAQgAtu5yO1ZN7I0pyN20Drg5qHqxQRm3HleYAozn+Ik5FYmqSq6mONgpPoOa2blGQEYIz+tZUsIbPmDODwCOlWtzZLQwLGWVpwJS3mE9Sc/ifar/kg7ljYlx3AqybZDMHCKGXgkc59qWWMKCpbk4yMdKu6bB7FNo3UAr97Gfm9M/wA6axJQbsdM5A/zx0qzMcxZViWHygNUR+ZgMAZPzccAVaMGZ28+g/76ooJfJwqgUVQHJDLHPBOO460EZbIA3Hg5poZSD0Ix0oBJZiM57Cus8Ykj9F4A/OpOg4FV8jsSGzipYzkZC/rQJoc7ADk496ZuGeCPoKkPAJP/AOqo9vOcEn1FAkPTP4damUmolzyCf0qQccUDR0fg2LfqEkuBwuB9TXpVrGRtAwPQ+lcP4BjykjkdW4P0rvoByMHPPIrkqu8jrpK0S7Gg28DPXFSA7cZ5OOlNAKqAMA+vvVSW4Cxsd3K8ZrBux0wi5aEr5nmeMgnb0wOn1pGiJj2s2WPU9KbbzIxVlOR3561ZOCB7HrWb1Rt8LsVGjOWXPQccdasxqJid6AKBnOKFXJJzyfUVPHvVgI2C7gQSewxSXdlOY63dVYoUyi98Uj4ZmKAj2zyaIVC5BYnvntTSTkknPPf+dUttTNpXdiLKqCMDnH4cVTlmjcKx5IGAP8atSovPTB6mqcjgNvBKgr8oA7mhDWpUlXzAxcs2B1zzVG6jUAlckEEgdquyyEHvk8DHFVZvmdtxHvtPX2oN9jPHTAwPeqshRnyPu+pHX3qzMrRoybevGB/Oooc4G/KgDjn3q13F5jGhYfe6Dp9T3qlImFx0KkgtiteURsrs3LKOhHBNZshAZiATwWO716fzqosxerKDQHJwy47c0VZx/u/jiirDU82BOevbqOtPBJbAJPcU1QQfqOQeKdGDlgDjnp6V3HkDgeODz2yKlTH4fypgB9M/U04ZBBOSfSkJkvUe1IeABnA9KN3PIAH1puQc9f8ACglIlXg+1OHB61Gp6d6eBjjvj1oGj0TwQhGmxEnqST+ddtaqWYHP0zXK+DYwul2/YbBXWWoB6EnPoBXDN6s76a90sSkALub8PWuZ1m78vMaFuck5HvXRXAJBC8HHA/KuZ12wmvJYwm4KW6r1/wDristL6nfhUr3Za0uSMp5qsSMbVrdt1PlLux6/jWRpNoI4kRUCoBjGM1sDEa7FOPb2qG7BVd5aD1J4z+lSSMEiOzBZfmPHBqrJII41YBmBOOBkmo7S4F1evHGFcpgYQnBx1x3NON2ZcvXsX5nXy8orb89QeMdxUMkpLjknAAx7Y4FPVSiCXO0Lx8zAfnVViIkdy2Wz8q9Mev1qpRluxQtsOkk2gcjae5rOmLFW2sGAxyOmafc3GAgAyOpHFUpZDvYMOT2OOn+NStjWK1BwcDBY7vUdqhk+8SpUk8AVMzBRnJxjAGep+lQEtgE9Rzx/Kgp+ZXfdjGMk9cUxl4bCnkCrAYvtTI2549RTQvucHp/hTuZt2KxQBmU5Jb5eOxNVpI2ZmVcccDJ7Vekb5iFyO5qJ1CRserHGD0xzyfyqk7BuUPKR/mEa4bn/AFgFFTbV7w8+yj/CirIuzys8ZXnPrRFnODjB7VEacp4BHGO3XNd55JYxk5x+NKflPXn0700HgHr+FK2dvHXHFIBQeRjp396fGMgjv9M1EoPHFTxrj/CgTHhaXHalFOQbmC+pxQCR6r4VULp0CqeAig55+tdRCuD8oGBxmuc0MCK1QDGQBxXR2+DHx0xxg9q8+Tuz01G0SwFG3bj6kdajMIPG38MdKsI3y4XoepxyKVdqzAqWOO3rTstyOZoZDCsCElRxwOOKrzbWfPY9Mf41cuiNmFOD1561R2HcDjuRurKemiNaevvMgvoi9syZPHdT096Z4fjubeYvCmGPyrI+ACDxj+gI/GryxmVVC9Opwe1Z140EcmLgFIpTjz4R8ynnAOTtx7nHPerouzuXLWLh3NyWyubqQO87SSjgMGUBPQMPb8a5ycoNkRLNKAQ7hsknOO3AHbFSuxvY5SbqJXbkpBA0Zcj+I84B6n0qpFbCJQoRo15Khu65wPxrWtUjLZfiLD0pQXvP8LD4ziRtwXHb8qr3ISSRSykKG3ZI7j0q6qoUXLEADGT1x9KgkRQQyISw555rnTN2RSoFVGY4P8vrUBwY2AOF65x1q24yMfMcnBNVJFwxXt0H0pFkZAxleRnnHFSA7vYdOaGAH0x1pAA4PADH17CmQ4XEZAXYrwPXPaopMj7oJ67varMy5VMkciopR94EkcYIH/1qEZtGY1ruYszck5OFFFXVgXaMlicdcmiq5mLQ8bKnJzyB70AAH/PHvUgXjsQTjHvQoJ/iwf1Ar0zxxQTgAHk9/SnJjp1x604A9P60oGOcUgHIuccHH1qYD0qNOgyeaeTg+vpQIUVLAN08Y77h/OoRye1W9OUPfQKem8UPYqCu0j1HRo2eMZOAORnvXToNgAUcAYFYukAhY1OOP4fT/GtpnOFA5fbwOleZN6nsKLasWFkYKcqM9vrUjDjO1Rg84qqpYgBgOR0FTklVXBKkeg4P1NO9zJxs9BJD8wLEgjjBpkIBmO4kr9elKXbcSDyelIgI5OMg+lTcLPYsD5VA2/ORjpz7VFOm8j5iCDjp/PvUkaksCcMCec/56UpjHzOxViDjBPH6VdtCOaz1My7iCsDGRkkk4/rxzVJlKD5jlg27g4B9jWpKgCEEbuxqi8YMg2kZGSTjI5/TFZSlrqddPYiOSRxhm7tzkdahlHUKMYPYYq30GfmznBycZqtcHaqnOT1IHAFKPYbIs5wpACgfdPeojH87E4z0AHHNT7C7EBeGHfjipEjDMMsNy9D2FDZZTkXaAWHyAZOOKBt2KVUEZIx6/WrBTruYHnoRmmeUeWBPuTj8hTuLYiYHgbQOOMdB9agkbLDGS2AdvTPvVwIiqM5OAfvVXuGKqcgAdif6VSMpsq/P2PFFLuf+4v8An8aKdjK54+pyB1I9aQLhj+lLgnqSDjg4peVBK+nOa9M8oeBn5eTxmnICGOAcdM0yNuoB4Papu3U460CY3oRjjPpS8Z56D3ob7oxn0pqcnnAFADl59eO1X9HGdTtvZu9Ul9xVqwkEV7A5PAcE0nsVB2aZ67osjM24bfQA1uoqsQwJ5weD/n1rn9Ew0QweSOR/9atsMxIP8JHpXmyR7Kl2HwNuc5LZzyD0qWbgccfj/Wqpb5+Hxk1C9yFY7nwAcYrNu2hXK5O6LqqCvBzn1PWpNw2hAMknke1Z0M29HfeQc4Hf8DVmBg64cgMuccZ5pcwOnY1FADg/N1wB3B9M9qHKMuNvOQCO5P8AjVdGUfeOR0z2qx8rqyljn2HatUzlcbPUqyphdx4HGBmq4jC8rgHoMDoKty/dIGSx55AI61XWMY+b5sdCw4z/AFqJLsaQdtyvMmIwwG7bxyP5f41TuFPO/d8vTbwCPb/JrUkyozuHsD3qlcIki/OASD03Y59KSdjRO5UhyRu43Y4APB981KVJPy42d+2fWiOMkruIYDjaD09akLkJ3YDhuMUmtTS5DIohUrH87k/lVdlJwR1BwemcVO5QMAi5xnk9KjgYeZliuB2xnIpoNiTyDjjOVGT6fnVK5QkdcgjJ5zWwOZHBHDDOQfz9qqzWzKv7vJY4yAOCPeqTMpK5i/8AAX/76xRU7KoYjzWHsF6UVXMRyPseNDkGkB4z+FKATnHGO9HHORXpnkiYwd3QdMCpUI28ev8Ak0xgcEZ/KmRE7Bn+VAi1QABwOBQtOFMQgHqaUEggjqKKUdKRR6p4dmEllEwYkFQeO1dAjyBN/QY9M1xXg+ffYxAnhRtPv/niutebECLyACcg+tcFRWbR61N3SZUv7o/Nt9cZ6VlyaokmwhmL+p7+9Rat5jRMoxyMtxztJ70thbpKkcaFd+4jk4XGKiMFbU9OmkldmxBIZV80xyBVI+cL8gHrxWvEeNxkVwQMHpz7Gs22guLYBop1ZyQxiAOGHY+n5UC9KPIrK4QN93GR7jFTOCRjL3vh2Noy7Yj95B33Dg/WnRyuVB3E9h7D0+lZKXcTD5WyvdR1X8PSpo59xjPIBOM/j/8AqrF3RlyG4A0gC/eUHpnsfpTpEGAOowTz0HPao4nVwELYxzyeaYG3DbgZP3QDnFa8yOblZHJjAw2Sep7mq0qDaOAfduMVe2iNmU8n2Ocf/XqFyCCcZ+vNJpDTZU2D+L5j0OP6UOoDcKCxzgE9BTm3AjkY/UUqD5Bg8jnJGKg0uVbmNFGIwSw6Ac1S3lSBtDevt+NbEkAaNgT1HB6CsXUEeEt1PH+cVpHUObQuae6uzAjnquT+tar27Km1iPVsHpXG6fq0SXccZYCUuCox1P8Ak13KOAq4POO/OfeiSsS23qZpsxk/KtFahdST86f9+xRRbzFzPt/X3HzP1GOop6pkDpUMUgyA2T7+tWVZR1IH1NeqeOyNsLnjJqOPgDAxTnYSHH8A6+9KBzjHI/GgCVeAOOtOzSDG3FO7DPWgQo6UoOKaKWmUdV4OuCIniLYIbOB2zXali+3k4HSvNfDbldQCLnLL268V6XAA0S9gB+dcVdWkephJXgrmXqY3yqWIB6Hr83Wm6fCZboBTGkZz94HJAPcVprF+9EvQfdGRUsdoqPkKvrgjv9Kx5rKx6ilZWROLqZpmkM5mf7pDLnH49qp3M2cldpA4BIwc+5q+Yk3AMAFAxwcA+9QXSZiZ48GLBBU9evNQ5czM0kuhjSuU2ttBC9D3X2p1pqyw3CxSNhiwMak9R3x79KbMFZsgZGehNcx4jhmhtzLATvgdZVI9j/n860jFS0ZlNtM9fR8RMSceoxUkQCxl+QW5GeM/Ss3S7iO80m2mVg0cqKwOeNpGea2kUPEGxxzgnpWNu5hKSRGEwm45YH8MVVkyOhXn9Kss2CUySRwRnNQXCkcZ+uab2Er31MiW6McoBwRngAd6vWEonlX5Ttz0b1/rWBqMwim52hT0z2qHw9qhk8QTWxKkqBIPcH/69Pk0uaS7HbzRhVVdxbPPPSsXVbTzFLZbI6gdq3CWyrFuO3PSoLiPcpcEDPGR/OmzGOiPFfGLXOjT219CCTbyBvqvf9K9P8K6mdT0xLuOUSRSjC5XBGOD/wDrrm/Gelrd2U6vgMAfo1Uvg1qbSaXNpc5/fWMhjGR/BnI/rW00p079UO7UvU9GKoTnP60Uuf8Arn+Iorjsje7PmdJdwGcGp4yoHyjvWBb3BU+314rQguNw56V7djwjU3cbj2GSRSAn6VAkoPOePrUoOT8uD2zSCxOr9QfrnNOBzx/+qo1bkAjJqTkD0oEOGOxozSAY47/SlFAGhobFdUgwcDkfpXpUEwCKrsVUjGB7+9eY6WwTUIGYfxYz9a76wd5+AckED1/GuautT0cFazubETEgLEudvAPpVq1ZfmYMCw+bAGc/5/rVIK1shlZQIieRnvSW907zCC0jLMc8Nkd+B7+tcer2PWULq50IiN6oIVYvlzjjnnpj0qnqcAij4QiVRjywSSQPetHRtOhNpO19d3NvdqpnWLjBjAzkeuTwcdKpz+YLcTNDcvGoDO2wHZxkEnsCPWtJUpRSdjmhUjKbjF6L+vmcxfbHO6BdnU5HNZd5F59vKkybCV6evvXT6khOyTYVB9OoNYOpArbSBQTgccciphK5tNK1yD4e3ry6fJpjtt+yyNED/st8wzXqcWGi642qAR6ivEfAt15fi+8hdgfNQNk8/MO35Gva9OcG3G/BJAzgZFXUj75wTfu/MIIwq5Bz2OahuE+bJBOeQSKutlM9emAR+lU55C3zOcFeeTWbSSCDcpXOW12ISIwAyRyD0rj/AA9M1v8AEbaM5ltDjPTg9a7fWCrEhwCSMZ7e5rzzVJTZeO9CuU+VZHaBiueAa1papoubs0e1xTfuggCkg5Jz3qKRtzZGB7Y6UlvyoIxz1BFTTqo5I4Pf0qLNq5irJ2OY11WIO/cVIxnGOPSvM9Jc6L8QoGQ7YNRjMbA9Cy8r/KvVtYDeXkfQ15P49X7I1ldqMNDdI64HvzWlHW8e5pLSzPXEeIouJCBjpzRWakpZFY9SM9R/jRXPynVr3Pl9H+bHQdhViKYjBHQVXKDPQcmnAHJ/x5r2j581ba56c9K0IZ93P51zqMQe2au28+0jmpYzo4yMZ/lUgIB68+may7e4yQO1aMThlyMVImrEmPWnAdAKQetKB7UAPiOx1Y5BBBBFej+GFBtkl9Rk150inYeuMfnXp3hSEmwt1I42gD2rDEaI7sG9WjUumieNBuJdchVwcE0ukx2sUga5mWNPvbtu4hgeMY5q3NBgbtiHjj2pi24lkDlMnocjrXAp8rueupJ0+W4k99NcuHhEzRruG8Ljg9QMk/lRLq1xCJI5ZXWOcbZd0PUYxgqDQyeTuZSyAsDx2qncStI5LlyAeDtA/Oq9pJu9yFCOyWgy5nEoAjmjl45zwSe+R1rF1JmSFy/BAwcjk1pzWvnIfMTPHTaKyNQjIR1jkcKBwGyQR6VUEgk29Eed2V4bPxmk4BGS3A9x0r6A0O6V7RGzn1xXzXrMj2OupcKBmN92O1e7+Ab2K/0kPCwZMjAz0yOn9PwrevHSMkcEXdzgzqZ2ZsAjrzgCqc7MA2Vzj0bkGtIoq4Vlz2z7GorsFQ24HcMYCscEH1rllG6uXTlZ2OUvCxkyw592Nee+O4jHPplxgL5N3G3XoCa9L1GNmLHjPWuB+IyqNH3AHejo3/jwrWg9UXW11PXNJlMkCMMFj79vWrd0rHnOTjJyKxfDbg2ELFSCRyPqO1bJkG3DkAHnGKI/DY56itO6Of1EFQeBznivJvitIqabHGPvGRePxr1rVmwQQDkevSvEvixcs11BEckM26tKC94dZvkv5HqdjMrWNud7cxqeB7UVjaVfqul2Y2g4hQf+Oiis3B3OnTseCMuUKjjPeljVlJDNmmgnkDrjtSqTkhs+teoeJYlHSlBIpo6UtIZcilKgdfetG2uAMc/UmsMHFTRzFec0mhnTwThl5PPvVpSDXOQXODyef0rSt7oZ5OR6d6QrGuCACBx9K9d8Ox+RYwr0G0A/kPWvGoJlkkTacEsAK9jsJttpbsgOSADz1rmxOx24JXbSN5QRuIycU4KoBBCqDxj1qC3kDRFWyDnqvf8AGrDOEzuBAx6c/WvPPQ5WtCu0CcgsVUDkkZqKO3VgyjOwdCT1P0p7TZ5JIK9AFzUT+ZnJjcE92wfyqHJGqi9mQOcfKDuGT8x/lWPqMYY7mUjB4x0rbdtxIYEZ/hI4rJ1DEXAIIYHHHb39MVcJ6lctjyrxfp8RvIHmBEbMY2KnoexFd18Eo2sk1O0aUyRb0dOMFcggj9K5nxhZ77dyvOPmwK6L4MSNcNeSccCNWI9RkH/Gu+TvSPMqQtW5u6PW3i4UsDxwSOtZt/nkBy2TyDxzWuAQzHAJA71mX6hmYAEf1rlnHQdCT5jBv5h8zfex/nvXnnxClzpbkqMMy5PTuK9F1C32gkj5mO7HavNPiOSNN7AeamQPrWlDdGtVq10epeGW26fEep2jn8BWjNIQvy5JHTHeud8GTO1ikZO5VUH9K2b+RUG049SRWU20ilTvUsZ+pTK4+YEY6HOTXifxVXN7bNnjOMD0r1bVboKWO4BB7V438QZzPdIsY3FRuGOa6cN8VyMXTUabNfT9YmSwtl/uxKOvsKK5SGZDDH86/dHf2oro5EQqsbGF1Ht1xinAjoQc0g5yBxxSjO48HArc8skGRn0zS5GPT60wEnnnNSY9KQC0UUUxkiPirEExX1qopx3pyHnnqOfrSsBsQ3BXDfjXvOhYuNNt5IyTuAPT1r51ViOufcZr3D4T6mLzQY4nYGSA+W2fbpn8MVzYiN4nXhJ8sz0OG32QkqoO3nk81A+6U55AJxg9SallmIj3Y4Hp1qBpWtogVcCeR1jU+merfgM1584pvQ9KDlZye5oW9rDEB5xQuR6Zx+FWXktuzOf0NU2dEBSFQF/vDq3uTURR9oYj3NXzRholc5nGdR8zY5jZs2JJhE2cDeuQfrjpXNazYtNL5ltJtRWKsPT1q/qUBKlhgelVoL6S4AS5lQeUvlr/ALQJ/i9x61KcZdLM6aalT9690cP4htdiMRuyQTwOD6mrnwWQLFq3Uf6Up9h8oq54oUwRswIOMg8cVB8J18qTWFH3TMjY6Y+Wt73pu5NaOqaPXDgKASNvpWddqAVbqxOTmriyfuzuyPlHXnA7VRvSNxyc56gdqzm9DlpRaZnX2DAxIxivKPiauzT1PHyuDx35r0+/lJtyiH8TXlPxJkzpjox6EYzV4fWRrUjaNzvvDbssMbRKACit+lWdUutyAAAHqeeprD0Vpm02yaFCztCnCDParGpQ3qxF3ikiGe69Khx946ozirO+pi63fAoULc47V5hqUzTazk5+VSR/Ku21Fw8vlqTLI3PHIFcLcBhrNzuOdq7ePr/9au2jGxxY2peNhhtYCcmFST6Cin7T23Y+tFb3PJOdp6kk8e3FNB6/TFKpHT8asokBGc5AFO6//XqNSR2Ofcd6f0bsM1ID6KQ8DrQcYOelMBRTwR61DuPpTg34UWC5Mhz15Brq/AGunR9bUO5W2utsbH+638J/pXIqcnkCpgcpyeDwcGolG6sy4ScWpI+prWcSxJtbIPfjmi+gMtkD5e/DBh6jHpXnvwz8T/2hpwsLp/8AS7dQmCfvr2avTdPl8xdoBOBXl1IckmmezTqc0OZF1FhVsLul27fnXhT9O9XPthjQLb2iIxH35MHFQxKqKAFCsfyrUtFg2kSAbuxPQ100ITm3yuxwVnCKXMnL+vuOO8SaddamF/0uS22NuBhULn6+1ZH9nXEcey5eJ1DBi4XBYjnJ/wAK7/UWhXcEwFxg89a5u/kXa+TgnpisalL2bte524et7SKVrI5DxOCbByDnAIIPes34QS7m1heeJIz19jVrxTOIrWQO3y7eR2rD+ErMy6xIfumSMD8mP9aq37tlzs5KJ7CXARcHBz171nXkwJJOeDxzn8qrfbWKHe2AoA696z7u7XBJkUjOMdcVyS1ZrCny7jbqRkBBJKnkYNeZfEMiSzyCAQcn6eldjf6oDnklV49PrXD+NJFazbBByK7aEbM58Q7pnf8AgX7fpmmLrLhb2yMCAW8QxKE6EqOjfT0zXaXOq2F9pfnQS7/MyRlSCPbHoK8V8J+Nn0fSorG9jkmEI/dyJ/d64IqTVvHl1c7hbwuFI/iIUD+tdMZVI3ilozgqKnV99uzRt6ve6faNqeryKoUr9mj+UAlxgk4/r3ry0uzzSzSYDzMXI7gdhTryaW7m826k8xgThR91fwqFiDznOKqKsY1JqWi2H7m/uJRVckEk8c/WitLGNjHHUU4dCM+9NpRgnocVQxQSTz9aUtt4BI5pqKWNTCEH1pARBznqPrin78+vPalkgZen1qMgqcGmLUUtz/jSAjPHUUo57nilC88E5oJaYqtgY/KpVbnjrUHTGM0qvx15oBNo0dOvJ7G6jubSTy54zkN6+oPsa9x8FeMrfVIQ2QlyBtkiJwR/9b3rwEPnr161Pbzy20yy28jRyqeHU4IrKrSVRHTQxDpPyPrO1v2bB3rg/wAJIzVlr5YlA3EJ1Ksea+fNC+I13ZhY76PzVH8adfyrpF+IlhImTIyN2ABGK4nQqQ2PRVahPfQ9Xur6IrkFifUHiuV1i/VZNytwDkgevrXDXnxEgVCISsmem0VyOreL7y8+VDsU8Ek5qo0JN6h9ap017pueMtaE8n2SFtzt154HNdT8Ko4l0y5x8zNPuYfRQK8aW4+dmJyzdWPU1v8AhzxJcaPdCW3ctESN8efvV0Spe7ZHIsTepzPY+hbGC3k15Y7tQ1s0ZeFc8HBGdx/Kukv7awW0byLaBC2AWVAeK8f03x9p9yEFwdki/d3HBFatx4vtXtl238GOvzDt+HU0qU1TTi4BiISqtTjPYreMrOySPOAkxkwjo2M+xHfNcH4/lSFI7OLmWQhSAe3c49Km1fxXB/aS3ECJfyoGCowzEuR1+o65rk7ieS5uZLi8kMs79WPQD0FOEbakzqtK17iOwA46DpTeqnr7UwydBnP0pGbI/i9zitLHKIWz6lTwaZnnHOTx6UjZLc//AF6aTyc/mapIBenG6ijJHGSMUU7Ac2zMvRm/OnKzY+8350UVocd2CyyDbiRxkZ6083dxGvyzPRRRZApSWzHG/uhx5x/ECk+0SnILk/hRRSaQ+eXcas0mAd59aRbmXH3u2aKKBcz7itcyfMcjI9qeJXyee/pRRTKuxRM+OtOFw4wOD9RRRSGmx32h/b8qPtD+35UUUF3YfaH9BSee2Oi0UUWHdii4fPQU5bl8jAUUUUhxZOty4IGF5AqWO4OeY4zgnqKKKktMsxzsy9FGD2p4cnHAGTg44ooqeoyMOSzAgYGKKKKpDFPQe9AGWA6ZoooYkQmVlOAeBxRRRTA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depressed, atrophic, purpuric, and scarred areas characteristic of atrophie blanche.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_38_4719=[""].join("\n");
var outline_f4_38_4719=null;
